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CHAPTER 1
GENERAL INTRODUCTION

Generai introduction
INTRODUCTION
Chronic Venous Insufficiency (CVI) of the legs is a complex of symptoms, caused
by continuously elevated intravenous pressure (due to upright position).
The increased venous pressure in the legs of patients with CVI is in the majority of
the cases the result of venous reflux. There are several causes for venous reflux:
1) primary varicosis, including perforator incompetence. According to Feuerstein
about 56% of the venous leg ulcers is the result of superficial venous
insufficiency (both primary varicosis and perforator incompetence).'
2) post-thrombotic damage in the deep veins. As result of deep venous thrombosis
(DVT) the valves of the deep veins are destroyed. Sometimes there is even
residual venous obstruction. Post-thrombotic damage forms in about 44% the
cause for venous leg ulcers.'
3) in less than 1% other disorders, such as congenital valvular incompetence, are
the cause of CVI.
CVI leads to the development of skin abnormalities, often resulting in chronic and
recurrent, sometimes painful leg ulcers. Because of these skin disorders and leg
ulcers, patients often visit the dermatologist. Leg ulceration and recurrent leg
ulcers form a daily problem for both patient and doctor.^
Patients with CVI form a considerable part of the patients seen by the
dermatologist. In the university hospital of Maastricht 16% of the consultancies
concern a phlebological disorder. In the general population the prevalence of
varicose veins is estimated to be between 15 and 55%.^ In the study of Widmer
varicosis was seen in 55%.' Major varicosis (trunk varicosis) was seen in about
10%, which is three times less than reticular veins are seen. It has been estimated
that CVI will develop in almost 50% of patients with major varicose veins.'' CVI
(including skin changes) was seen in 6% in the general population in the study of
Widmer. The estimated prevalence of CVI by Callam is 2 to 7% 7 It is unclear
which percentage of CVI is caused by post-thrombotic damage. In a study of
Nicolaides 35% of the patients with CVI had deep venous insufficiency.* The
prevalence of leg ulcers is estimated around 1.2%.'-'°
In this introduction I will briefly summarise the current knowledge on CVI,
relevant for this thesis.
CHRONIC VENOUS INSUFFICIENCY
Untreated CVI leads to a sequence of microcirculatory changes of the skin that
result in the clinical sequelae of oedema, corona phlebectatica, hyperpigmentation
("dermatite jaune d'ocre"), dermato- et liposclerosis, atrophie blanche and finally
ulcers [figure l ] . ^ " Damage or incompetence of the venous valves and
subsequently reflux in the superficial, deep or perforating system is the most
important cause of CVI.'2 Venous reflux leads to a relatively insufficient pump
function of the calf muscle and an increase of the walking venous pressure at the
ankle. This increased walking venous pressure induces dilatation and a tortuous
appearance of the capillaries, leading to capillary leakage and oedema formation.
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From this point on functional changes of the microcirculation induce many
pathological alterations leading to the clinical syndrome known as CVL"
FIGURE 1
Clinical aspects of CVI.
An important clinical classification for severeness of CVl is made by Widmer in
1981 [table l].s The Widmer classification is based mainly on clinical symptoms
and is still the most widely used because of its simplicity. Also in daily practice
most dermatologists categorise all their patients with venous complaints.
TABLE 1
Widmer classification^ in symptoms of CVI
Class
1
n
in
Symptoms
Corona phlebectatica paraplantaris
Oedema (sub-clinical)
Oedema (clinical)
Pigment disorders
Dermato- et liposclerosis
Atrophie Blanche
Leg ulcer
Leg ulcer in the past
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A new classification, however, was developed because the Widmer classification
and other classifications were not precise enough, resulting in a very large inter
patient variation in one group, which makes it very difficult to compare certain
groups of patients. Especially the haemodynamic differences in these groups can
be very large. In 1995 this new, more thorough classification called CEAP (or
Hawaii) classification has been designed [table 2].'* The new classification
categorises patients with venous diseases on the basis of different parameters:
Clinical, Etiological, Anatomical and Pathological. It must be realised, however,
that patients should be reclassified during time, for instance after treatment. In
daily practice this classification is very time consuming for both the doctor and
patient due to all the investigations, and is therefore not very usefull. The most
important disadvantage of the CEAP classification is, however, that also this
classification is not complete, because haemodynamic disturbances are not
classified. As result, for instance, a patient, which is developing a post-thrombotic
syndrome, is not categorised correctly.
Besides that it is important to classify a patient, it is important to investigate the
severeness of the patients disease by clinical symptoms, anatomical and functional
changes of the venous system. Therefore it is necessary to elucidate underlying
abnormalities in the venous system and to determine the severity of CVI by
quantitative measurements.
Investigative techniques can be divided into anatomical investigations (duplex
and phlebography) and functional (plethysmography, duplex and direct pressure
measurements) investigations. Direct venous pressure measurements in a large
group of patients show a linear relation between ulceration and walking venous
pressure." An increased incidence of ulcers is associated with an increase in
walking venous pressure irrespective of whether the venous problem was the
result of superficial or deep venous disease.**
During the past two decades, new non-invasive techniques have been developed
to study microcirculation. The techniques most often used today are laser Doppler
fluxmetry, transcutaneous oxygen measurement (TcPO2) and capillary
microscopy.
MICROCIRCULATION
All clinical signs of CVI, including the leg ulcer and arrophie blanche, are the
result of the alterations of the skin microcirculation induced by the walking
venous hypertension. Studying the microcirculation is therefore of great
importance for understanding the clinical syndrome of CVI. In the past decades
several non-invasive instruments have become available to study the
microcirculation of the skin. Non-invasive techniques for investigating
microcirculation are capillary microscopy (direct)"-™, transcutaneous oxygen
tension (TcPCfe)".™, laser doppler flux'** measurements and different forms of
plethysmography.
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TABLE 2: CEAP classification" *
Clinical classification
0 No visible or palpable signs of venous disease
• 1 Teleangiectatic or reticular veins
2 Varicose veins
3 Oedema
4 Skin changes ascribed to venous disease
5 Skin changes as defined with healed ulcers
6 Skin changes as defined without healed ulcers (active ulcers)
Etiological classification
Congenital
Primary - with undetermined cause
Secondary: - post thrombotic
- post traumatic
- other
Anatomical classification
Superficial veins
1 Teleangiectases/reticular veins
Long saphenous vein
2 - Above the knee
3 - Below the knee
4 Short saphenous vein
' 5 Non-saphenous vein
Deep veins
6 Inferior vena cava
Iliac vein
7 - Common
8 - Internal
9 - External
10 Pelvic vein
Femoral vein
11 - Common
12 - Deep
13 - Superficial
14 Popliteal vein
15 Crural vein- anterior tibial, posterior tibial, peroneal
16 Muscular vein- gastrocnemical, soleus, other
Perforating veins
17 Thigh vein
18 Calf vein
Pathophysiological
Reflux
Obstruction
14
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The microcirculation of the skin can be divided into a nutritional and a
thermoregulatory part. The laser doppler fluxmetry measures mainly the flux of
the thermoregulatory vessels (85%) and in lesser degree the nutritional capillaries
(15%).20-2i TcPO2 probably reflects for a greater part the function of the nutritive
skin capillaries.^! With capillary microscopy capillaries in the skin are seen,
which probably represent mainly the nutritional status of a certain area.
A number of abnormalities in relation to microcirculation have been discussed in
the literature in patients with CV1.
- Changes in capillaries. With capillary microscopy Fagrell observed dilated,
tortuous and elongated capillaries in the skin of the medial ankle region area in
patients with CVI.22 Capillary density seems to be largely unchanged in skin with
oedema, cyanosis and hyperpigmentation, but is reduced in patients with more
severe CVI. Especially in atrophie blanche a strongly reduced number of
capillaries is counted, even reaching zero.^
Patients with mild to severe CVI, including morphological changes, but without a
reduction in the number of capillaries, already have a reduced TcPCb values. A
decrease in TcPCh values can be correlated with a reduction in capillary density.
In the centre of atrophie blanche values may reach zero.^
- Changes in permeability. Around the capillaries halo's are visible, which consist
of oedema, polysaccharides, haemosiderine and fibrin.^ The diameter of the halo
is smaller in healthy controls than in patients with severe CVI.^^ Transcapillary
diffusion can be measured with sodium-fluorescein. An increased permeability is
seen in mild CVI, not in severe CVI.-^* This might be explained by a fibrin cuff
around capillaries in patients with severe CVI.
- Increased fibrin formation. Fibrin accumulation (perivascular cuffs) in tissue
close to ulcers has been demonstrated by several authors. The theory of fibrin cuffs
is from Browse and Burnand.^ They suggest that as a result of continuously
increased venous pressure, capillaries will dilate, resulting in increased leakage of
fibrinogen. Around the vessels this will be converted into fibrin, forming a cuff
around the capillaries. The function of these cuffs is still unclear. Some authors
find a decreased diffusion of oxygen, while others did not measure differences in
oxygen tension in lesions with or without fibrin cuffs.*-*
The microvascular skin flux (the concentration of moving blood cells multiplied by
the magnitude of the median velocity) is measured by laser doppler fluxmetry.
Laser doppler flux is increased in patients with CVI.^2 Flux is already increased
when macroscopical changes of the skin are minimal.** Both a decreased
vasoconstriction response as an unchanged response in patients with CVI have
been described.si-^ The same is true for the pattern of vasomotion. Patients with
mild to severe CVI showed no alterations in pulsatile flux waves, low-frequency
vasomotion and high-frequency waves, whereas vasomotion frequency and
amplitude were augmented in patients with severe
Coleridge Smith suggested an accumulation of white blood cells in capillaries in
the legs of patients with CVI.'5 An increased ratio of red and white blood cells was
found in the long saphenous vein. Trapping of white cells induces activation of
15
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these cells, resulting in degranulation and release of oxygen radicals and
proteolytic enzymes.
Recently, in 1993, a hypothesis for the pathogenesis of venous ulceration was
suggested by Falanga en Eaglstein.*" They suggest that venous hypertension
induces microtrauma of the endothelial cells, resulting in an increased capillary
permeability. As a result macromolecules, such as fibrin and other
macroglobulins, leak into the dermis, trapping growth factors, contributing to
slow healing ulcers.
Another interesting theory is suggested by Bollinger e£ rt/.^, because for this theory
both histological and capillary microscopical evidences are found. In this theory
microthrombi develop as a result of change in blood flow in capillaries. With
sodium-fluorescein capillary microscopy, a decreased flow is observed in atrophie
blanche lesions. The sodium reaches the centre of a lesion much later in atrophie
blanche lesion than in healthy skin.3* Also with electron microscopy and light
microscopy microthrombi could be found.-"
Whether these changes in capillaries are merely a result of venous hypertension or
whether they play an important role in aetiology is still unclear.
Enhanced fibrin formation and decreased fibrinolytic response might play a role in
patients with CVI, which could stimulate locally the formation of microthrombi.
Recently Falanga c/ rt/. found increased values of fibrin degradation products in
plasma of patients with CVI.''" An increased total fibrin-related antigen (p=0.04)
and increased D-dimer levels (p=0.006), a degradation product of cross-linked
fibrin was found in patients with CVI with and without ulcers compared with 15
healthy controls. Fibrinogen degradation products were in the normal range.
Patients which recently had undergone surgical or invasive procedures, or
patients with cellulitis or recent infection were excluded. It was therefore
suggested that patients with CVI have an increased production of fibrin.
There is some evidence for a decreased fibrinolytic activity in patients with CVI.
Increased levels of plasminogen activator inhibitor-1 (PAI-1) antigen were found
in a double blind study in 20 patients with CVI (venous leg ulcers) compared with
healthy controls.-" Increased levels of PAI-1 activity can be a sign of diminished
fibrinolysis. Also Veraart ef <J/. found increased values of PAI-1 activity in patients
with Klinefelter syndrome complicated by skin changes (including atrophie
blanche and leg ulcers), clinically indistinguishable from the lesions seen in CVI,
but without objective valve disturbances of the venous circulation.^
TREATMENT OF CVI
Compression therapy is widely used in the treatment of all kinds of phlebological
diseases. Because in daily practice it has been proved to be effective for venous leg
ulceration, it has been generally accepted as first choice for treatment. It has been
demonstrated in only a few studies that under normal ambulant conditions,
compression therapy is superior in treating venous leg ulcers compared with
treating without compression therapy.•"•+• Although practised by many doctors,
there are hardly any 'evidenced based' data available on the favourable effects of
16
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this treatment in CVI.^ s-tf It is important to realise that before compression
treatment is given a thorough analysis of the patient's venous disorder should be
made. If possible, restore of the venous haemodynamics with adequate surgery
and/or flebectomy or sclerocompression therapy should be performed. If these
treatments are not a serious option or even contraindicated for treatment of severe
CVI, compression therapy should be given. Compression therapy is of course only
indicated when arterial diseases have been ruled out (ankle/arm index > 0.8).
After healing of venous leg ulcers, recurrence rates can be reduced dramatically if
compression therapy is persisted. After an average of 30 months wearing class III
stockings, recurrence rates were 16% in the compliant group and 100% in the non-
compliant group.*
The importance of compression therapy in the prophylaxis and treatment of deep
venous thrombosis (DVT) is less clear. Compression therapy in the combination
with low molecular weight heparins (LMWH) seems to have a synergistic effect in
preventing DVT.''* It has been suggested that compression therapy can be effective
in the prevention of acute complications after a DVT. Partsch ef a/, treated a group
of patients with acute DVT by early compression therapy and ambulation, beside
standard anticoagulant therapy."" Concerning the occurrence of pulmonary
embolism, the group performed no worse than the standard treatment with bed
rest and anticoagulant therapy. Compression therapy prevents the development of
late complications, such as the postthrombotic syndrome.so-""' Recently a study of
Brandjes showed a decrease in incidence of the postthrombotic syndrome in more
than 50% in patients wearing compression stockings class III for 2 years after a
DVT compared with patients without stockings.^
DEEP VENOUS THROMBOSIS
DVT is often seen in clinical practice and is associated with significant morbidity
and mortality. There is a clear relation between DVT, resulting in the
postthrombotic syndrome and the symptoms of CVI, like atrophie blanche,
dermato- et liposclerosis and venous leg ulcers. In the pathogenesis of DVT
disturbances of haemostasis are important.
HAEMOSTASIS
Over a century ago Virchow summed up the conditions leading to a DVT as
hypercoagulability, damage to the vein wall and slowing down of the venous
blood flow. These principles are still accepted, but extensive research has revealed
a complex system of factors that induce or inhibit the formation of a haemostatic
plug.
The haemostatic system is the result of interaction between platelets, vascular
endothelial cells, plasma coagulation proteins, fibrinolysis and inhibitor systems.
The haemostatic system is regulated by a balanced system of activators and
17
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inhibitors. Thrombin is the central enzyme in haemostasis and thrombosis.^
Thrombin acts at the level of the plasma, the platelet and the vessel wall. It is one
of the most potent in vivo platelets activators. Activated platelets on the other
hand are essential in the process of abundant thrombin generation.
After destruction or traumatisation of the vessel wall a chain reaction is induced
which finally results in the formation of thrombin and fibrin. Three main
mechanisms can be divided. The first reaction after traumatisation of the vessel
wall is vasoconstriction and formation of a procoagulant subendothelium. The
second mechanism which can be seen is the adhesion and aggregation of platelets.
The third mechanism is the formation and polymerisation of fibrin.
Damage of the vessel wall leads to exposure of tissue factor (TF) to the plasma
proteins.^ TF binds factor VII. The TF-factor VII complex activates factor X into
factor Xa. The conversion of the TF-factor VII complex into the TF-factor Vila
complex is catalysed by factor Xa, with a much higher enzymatic activity.^ In
addition, the TF-factor Vila complex activates factor IX, which in turn can also
activate factor X into Xa [figure 1].55>
Factor Xa alone converts prothrombin into thrombin at a very low level (less than
0.1% of the velocity of full prothrombinase). Small amounts of thrombin thus
generated produce feedback reactions: activation of factor V into Va, of factor VIII
into Villa and activation of platelets.^.58
FIGURE 2
Schedule of coagulation.
TF = tissue factor
TFPI = tissue factor plasminogen inhibitor
VII, VIII and IX = coagulation factor VII, VIII and IX
18
GeneraJ introduction
Within seconds after traumatisation, platelets adhere to adhesive proteins in the
subendothelium, such as collagen, fibronectin and laminin. After adhesion a chain
of reaction is induced: changing in shape of platelets from a smooth disc to a
irregular sphere with pseudopods and the release of ADP, ATP, PF4, vWf and
TxA2. The point of no return is the activation of the fibrinogen receptor on the
surface of the platelets, the glycoprotein Ilb-lIIa. After activation glycoprotein Ilb-
Illa binds fibrinogen resulting in the formation of plateletaggregates.
Together with the activation of glycoprotein Ilb-llla, procoagulant negatively
charged phospholipids from the inner membrane of the platelets are exposed,
which is the so-called 'flip-flop' of the membrane.^
Factor Va binds to these negatively charged phospholipids. After binding, factor
Va serves as a platelet binding site for factor Xa. For a rapid, massive generation of
thrombin the full complex Va-Xa-phospholipids (prothrombinase) is required.
The extensiveness of the clot formation is related to the location and the kind of
trauma. Thrombin plays a central role in the process and the amount of thrombin
is closely related to
-the release reaction of platelets and their flip-flop mechanism
- activation of factor V and factor VIII
- formation and cross-linking of fibrin
- activation of factor XI >
- activation of protein C pathway
- inhibiting fibrinolysis by thrombin activated fibrinolysis inhibitor (TAFI)
INHIBITORY MECHANISMS
Activation of platelets and coagulation are closely related processes. Over-
activation increases the risk of thrombosis. There are several mechanisms
contributing to the balance between thrombin formation and inactivation, by
which the process of coagulation stays localised. Two important mechanisms
occurs via tissue factor pathway inhibitor (TFPI) and activated protein C (APC).
Thrombomodulin is a membrane glycoprotein, present at the surface of intact
endothelium. Thrombin can bind to thrombomodulin and so looses its
procoagulant properties and activates protein C. After activation of protein C a
complex is formed with its cofactor protein S. This complex neutralises free
activated factors V and VIII, ^ ' damping down the coagulation and thrombin
formation (in this way inactivating both tenase and prothrombinase) and it
activates fibrinolysis by inhibiting PAI-1. The importance of these inhibitor
mechanisms is seen in patients with a deficiency of antithrombin, protein C,
protein S or with APC resistance, resulting in increased thrombotic risk."
TFPI inactivates the coagulation initiated by the TF-factor Vila complex. TFPI
binds to first to factor Xa.<^  This complex inhibits TF-factor Vila complex. This
mechanism ensures that tissue factor-induced factor X activation will stop as soon
as sufficient factor X is present. The plasma concentration of TFPI is very low but a
substantial amount is present in endothelial cells and can be released, for instance,
by the cell membrane binding of heparin.
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Thrombin, once formed, is inactivated by plasma protease inhibitors
(antithrombins).^ Antithrombin is the most important, contributing for 64% of
total antithrombin activity, a2-macroglobuline accounts for 23% and the
remaining 13% is taken care of by other antiproteases (mainly al-antitrypsin).^
FIBRINOLYSIS ^
The fibrinolytic system compromises an inactive pro-enzyme, plasminogen, which
can be converted to the active enzyme, plasmin, which degrades fibrin into soluble
fibrin degradation products [figure 2]. Two immunologically distinct physiological
plasminogen activators have been identified in the blood: tissue plasminogen
activator (t-PA) and urokinase plasminogen activator (u-PA). t-PA is released from
endothelial cells and u-PA from monocytes and leucocytes.** Inhibition of the
fibrinolytic system may occur either at the level of the plasminogen activators, by
specific activator inhibitors (PAI-1, PAI-2 and TAF1), or at the level of plasmin by
(X2-antiplasmin.
FIGURE 3
Schedule of fibrinolysis.
Plasma / PA-inhibitors
(u-PA) ^ ^ A . * / " ^
Plasminogen activator
Tissue
(t-PA)
Plasminogen • Plasmin
ct2 antiplasmin
1
Fibrin • Fibrin degradation products
- • = activating
• = inactivating
20
Generai introduction
DEEP VENOUS THROMBOSIS
In about 50% of patients with leg ulcers as symptom of CVI, a history of DVT is
seen.*'' However, it must be emphasised that a diagnosis of DVT must be based on
objective diagnostic methods and not solely on clinical grounds.
The prevalence of DVT is estimated to be 1-3 per 1000 in the general
population.^*' Incidence of DVT is increasing with age. With the introduction of
contrast phlebography it became apparent that in only 30% of the patients with
clinically suspected DVT, the diagnosis could be confirmed by phlebography.''"'''
Phlebography has been the gold standard for the diagnosis of DVT for a long time.
Phlebography is an invasive, painful technique with a small risk of contrast media
related complications.^^ The disadvantages of this investigation should be
considered.
With the introduction of compression ultrasonography (or echo) and duplex
scanning excellent alternatives for phlebography have been found.^ The accuracy
of compression ultrasonography and duplex scanning is especially high in
patients with a first period of suspected DVT of the proximal veins (vena poplitea
and h igher ) /^ The accuracy of duplex scanning in the diagnosis of proximal
DVT is comparable to ultrasonography.
Ultrasonography is the first choice for the diagnosis of DVT in patients with a first
symptomatic episode of proximal DVT. There are, however, several limits for the
use of ultrasonography. 1) In patients with isolated pelvic vein thrombosis echo
can be negative. In case of a high suspect pelvic vein thrombosis, venography
should be performed. 2) For the screening of asymptomatic population with a high
risk for DVT (for instance after hipsurgery), echo is not qualified. 3) The sensitivity
of calf vein thrombosis with echo is considerable less than for proximal vein
thrombosis. The spontaneous development of a calf vein thrombosis is unknown.
Probably about 10-20% of calf vein thrombosis will extend to proximal. The
necessity for treatment of calf vein thrombosis is therefore not clear. It has been
suggested that only distal DVT extending to proximal should be treated and that
DVT limited to the calf should not be treated, because the risk of pulmonary
embolism is negligible.?-^ A recent study, however, showed that the risk of post
thrombotic syndrome after distal DVT is considerable less than after more
proximal DVT, but should not be neglected, which causes concern about not
diagnosing and not treating patients with distal DVT7* 4) The usefulness of echo
in the diagnosis of recurrent DVT has been questioned, because normalisation
occurs in only around 50% during the first year.^ The use of the criterion of
compression is of limited value for recurrent DVT diagnostic management. At this
moment D-dimer (degeneration products of cross linked fibrin) has been studied
as potential aid in the diagnostic management of DVT. D-dimer testing can not be
used as the only diagnostic tool to detect thrombosis because of its low specificity.
However, it could be a valuable additional test to exclude a new thromboembolic
process in the first period of suspected DVT as well as in recurrent signs of new
DVT so-si
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The pathogenesis of DVT is complex. The risk for the development of DVT is
associated with a number of clinical conditions (surgical procedure,
immobilisation, pregnancy, trauma and the use of oral contraceptives), acquired
risk factors (malignancy, age, antiphospholipid antibodies and bowel diseases
(Crohn's disease and colitis ulcerosa) and congenital risk factors (antithrombin,
protein C and S deficiency, factor V Leiden mutation, prothrombin mutation,
hyperhomocysteinaemia, and dysfibrinogenaemia.
It is very likely that in the individual patient a combination of factors finally result
in symptomatic thrombosis. Interaction of several factors, such as the combination
of factor V Leiden mutation and the use of oral contraceptives, are known for the
increased risk in developing DVT."-^ It is therefore important to screen a patient
for thrombophilia so that adequate prophylactic and therapeutic
recommendations can be given.
The prevalence of the main hereditary factors associated with an increased risk for
thrombosis processes varies in different patient groups. A summary of the most
important hereditary factors of which the relation with DVT is proven, is given in
table 3.
A number of other abnormalities have been postulated, which might also increase
the risk for developing DVT. They are mentioned in table 4.
TABLE 3
Prevalence of main established hereditary risk factors for DVT **
Factor V Leiden mutation
Protein C deficiency
Protein S deficiency
Antithrombin deficiency
Prothrombin mutation*
Hyperhomocysteinaemia*
Dysfibrinogenaemia
Normal
population
5%
0.3%
unknown
0.04%
1%
11.5%
unknown
Thrombosis
population
20%
3%
1.5%
1%
7%
25%
unknown
* also associated with arterial thrombosis
THROMBOPHILIA
Thrombophilia can be defined as "the familial or acquired abnormalities of the
haemostatic mechanism likely to predispose to thrombosis".^ Thrombosis can
occur spontaneously in the absence of a recognised risk factor. It is difficult to find
out whether thrombosis occur spontaneously or that the patients has
thrombophilia. Clinical signs for thrombophilia include venous thrombosis at
22
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young age, recurrent venous thrombosis, family history of venous thrombosis,
venous thrombosis at unusual sites, recurrent fetal loss, coumarin induced skin
necrosis, neonatal purpura fulminans and heparin resistance. It is advised to
screen every patient with DVT for thrombophilia, if they suffer thrombosis before
the age of 45, or when suffered from the above mentioned clinical signs.**
Thrombophilia tests should be performed at distance of an acute episode and
whenever possible in nonanticoagulant, nonpregnant, and in the nontaking oral
contraceptive pill patient."
TABLE 4
Potential factors with increased risk for DVT
Potential factors predisposing to thrombosis
* Thrombomodulin mutations
* Increased levels of factor VIII
* Plasminogen deficiency
* Heparin cofactor II deficiency
* S2 glycoprotein I deficiency
* Increased levels of histidin-rich glycoproteine
* Tissue factor pathway inhibitor (TFPI) deficiency
* Thrombin-activated fibrinolysis inhibitor (TAFI) excess
FACTOR V LEIDEN
Factor V Leiden is a relatively new known risk factor for DVT, which seems to
play an important role. The first reports about the activated protein C (APC)
resistance came from Dahlback in 1993."'' APC resistance appeared to be a
characteristic of selected patients with venous thromboembolism, particularly
those who had positive family histories and were relatively young. In rapid
succession, studies directed by Bertina^ and Dahlback^ as well as the Leiden
thrombophilia study"", found that the cofactor responsible for resistance to APC, is
a previously unrecognised form of coagulation factor V. This resistance was
associated with a gene defect, called factor V Leiden mutation.
Factor V Leiden mutation is a specific point mutation in which adenine is
substituted for guanine at nucleotide 1691 in the gene coding for coagulation
factor V. Factor V Leiden mutation alters APC cleavage site of coagulation factor V
and produces a mutant molecule that cannot be properly inactivated by APC.
APC resistance accounts for about 20% of DVT, and for 50% of familial venous
thrombosis.^*-" Factor V Leiden therefore plays an important role in the
pathogenesis of DVT and might therefore also be important in the pathogenesis of
CVI.
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AIMS OF THE THESIS
1) Recurrent leg ulcers are often seen in patients with CVI in daily practice. What
is the prevalence of atrophie blanche in patients with leg ulcers and are
recurrent leg ulcers seen more often in patients with CVI and atrophie blanche
than in patients with CVI without atrophie blanche? (Chapter 3)
2) Microcirculation in patients with CVI is disturbed. Microcirculation can be
studied with laser Doppler perfusion imager, transcutaneous oxygen
measurements and capillary microscopy. Is there a difference in flux,
measured with laser Doppler perfusion imager, in atrophie blanche lesions
and healthy controls? What is the effect of artificially induced venous
hypertension on the flux in atrophie blanche, and on transcutaneous oxygen
values. Is there a different reaction pattern on venous hypertension in patients
with CVI with and without atrophie blanche and healthy controls? What is the
effect of venous hypertension in capillaries in patients with CVI? Can changes
in capillary blood cell velocity be determined with conventional capillary
microscopy? Is the effect of venous hypertension the same in capillaries in CVI
patients as in nailfolds of healthy controls? Are standstills in capillaries visible
during venous hypertension, and is there a difference between several levels
of venous hypertension? (Chapter 4 and 5)
3) A lot of patients with deep venous thrombosis show factor V Leiden mutation.
A history of deep venous thrombosis is often seen in patients with venous leg
ulcers. What is the prevalence of factor V Leiden mutation in patients with
venous leg ulcers? Is factor V Leiden mutation seen more often in patients
with recurrent leg ulcers, atrophie blanche or dermato- et liposclerosis
?(Chapter 6)
4) Microthrombi are suggested to play an important role in the pathogenesis of
atrophie blanche. Several anticoagulants are suggested in the treatment of
atrophie blanche. What is the effect of low molecular weight heparins on the
microcirculation in atrophie blanche, measured by laser Doppler perfusion
imager, transcutaneous oxygen values and capillary microscopy? (Chapter 7)
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INTRODUCTION
Atrophie blanche (AB) is a common skin disorder (prevalence 1-5%). It is
predominantly localised in the lower leg and characterised by a distinct clinical
morphologic appearance and the serious risk of developing painful and difficult to
heal ulcers.
The Frenchman Milian was the first to describe this clinical entity in 1929.' The
first publications in English and French literature under the name atrophie
blanche appeared in the early fifties.--^  Since then many articles have been
published about AB, using different synonyms, such as capillaritis alba, atrophie
blanche of Milian, livedo reticularis with summer ulceration's, livedo vasculitis,
segmental hyalinizing vasculitis, vasculitis of atrophie blanche, PURPLE and
livedo vasculopathy. This nomenclature can be very confusing [table 1] as some
synonyms are used for different unrelated skin disorders.'*-^
TABLE 1
Synonyms of atrophie blanche or white atrophy
Nomenclature
Atrophie blanche
Capillaritis alba
Atrophie Blanche of Milian
Livedo reticularis with
summer ulceration's
Livedo vasculitis
Segmental hyalinizing
vasculitis
Vasculitis of Atrophie
Blanche
PURPLE (painful purpuric ulcers with
reticular pattern of the lower extremities)
(Livedo) Vasculopathy
Author
Milian''
Wilson^
Maessen-Visch^o
Ellerbroek''
Metz5
van der Molen*
Feldaker'
Bard and Winkelmann'"
Bard and Winkelmann"
Pierard and Geerts''
Gilliam"
Schroeter'^
Milstone"
Shornick'''
McCalmont'^
Year
1953
1974
1996
1953
1974
1953
1955
1974
1967
1971
1974
1975
1983
1983
1992
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Because there is a lot of controversy about AB, a review of the literature has been
carried out on this entity and in order to summarise current knowledge regarding
pathogenesis. Particular attention is given to the relation to other diseases and
therapy.
CLINICAL PRESENTATION
The morphology of AB is very characteristic. Milian distinguished two forms of
AB: "atrophie blanche en plaque" and "atrophie blanche segmentair".'-'* He des-
cribed "AB en plaque" as a smooth, depressed, ivory white plaque, of variable
dimensions, from 0.5 to 15 centimetres, surrounded by a small pigmented ring of
several millimetres in width, around which numerous teleangiectatic capillaries
are arrayed [figure 1].'
FIGURE 1
Clinical aspects of a typical atrophie blanche lesion on the medial side of the ankle.
The morphology of "AB segmentaire" is less clear and has been clinically described
by Milian as a scar-like lesion on one segment, a leg or a foot.
AB is described in 9%-38% of patients with chronic venous insufficiency (CVI)A^
* The prevalence of AB in the general population is estimated to be between 1%
and 5%. The prevalence of varicose veins varies between 15 and 50 %, of which 50
percent will develop CVI.2'*» Especially in patients with recurrent venous leg
ulcers the prevalence of AB is high, up to 73%.'*-*>
Ulcers of AB lesions can be extremely painful and shows a slow healing tendency.
It is often underestimated that patients with AB and recurrent ulcers have
considerable disability and that the costs of treating are enormous.^
Women are more often affected than men, M:F ratio is 1:4.*'^ AB lesions can occur
at any age, but the peak prevalence ranges from 30 to 60 years.v.u.a. AB has also
been described in children.*^ There are no data suggesting a geographic or racial
difference.
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Differential diagnosis of AB should include lichen sclerosis et atrophicans,
scleroderma, malignant atrophic papulosis (morbus Degos), and scar formati-
on.29J<> Lichen sclerosis and scleroderma are mostly localised on the trunk, and the
lesions are often not depressed. Histologically, a thickened dermis and a band of
hyalinisation of the dermal collagen can distinguish these lesions. Malignant
atrophic papulosis are mostly numerous small lesions distributed more proximal
or on the trunk. Histology shows endovascular inflammation, proliferation and
thickening of the deep dermal vessels. An atrophic scar is thin and wrinkled and
shows no teleangiectatic capillaries.
In systemic diseases in which AB is described, the incidence of AB is unknown.
Systemic diseases in which AB is seen include scleroderma and systemic lupus
erythematodus (SLE).'W The author suggest an incidence of less than 1% in
systemic diseases is, based on literature and personal experiences. Recently a large
group of patients with SLE was examined for skin disorders, cutaneous vasculitis
was seen in 11% and livedo reticularis in 4%, however AB as special entity was not
recorded or seen.^
In case reports AB is described in vasculitis necroticans, abdominal aortic pa-
thology, cryoglobulinemia, thalassemia minor, essential thrombocytosis, glu-
tathion reductase deficiency, Klinefelter's syndrome, Sneddon's syndrome,
polycytheamia, gamma heavy chain disease, digital infarction, chronic myeloge-
nous leukaemia and lymphoma .3U3-H
It is however generally accepted that AB is highly associated with CVI, as nearly
all patients with AB show
PATHOGENESIS
The underlying pathogenetic process of AB remains controversial. Successful
fibrinolytic, antiplatelet and compression therapies of AB ulcers and the finding of
occluded vessels in histology suggests a combination of coagulation and fibrino-
lytic disorders in relation to venous insufficiency.*'••"-"*-" It remains unclear what
plays the most important role and whether coagulation and fibrinolytic disorders
are caused by venous insufficiency or vice versa. Drugs that influence coagulation
and fibrinolysis have been used since Gray e' «'• and Potter and Haberlin in the
sixties suggested that local thrombo-occlusive processes were the cause for the
ulcers that appeared in AB.-''"
There are several hypotheses postulated to explain the underlying mechanism of
development of CVI, such as fibrin cuff, "white cell trapping" and microthrombi.
Fibrin cuff
Browse and co-workers suggested the "fibrin-cuff theory". They stated that as a
result of CVI, a leakage of fibrinogen from the capillaries induces a fibrin-cuff
around the capillaries leading to a barrier for oxygen and nutrients.'*"This would
cause decreased transcutaneous oxygen values, as seen in CVI and especially in
AB lesions.** Recently doubt has been expressed about this theory, as fibrin cannot
be a serious barrier for oxygen; the fibrin cuffs are more an indication of a
disturbed microcirculation, rather than an etiologic factor in"CVI.^ -w
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White cell trapping
Coleridge Smith ef a/, postulated the "white-cell trapping theory".*" In this
hypothesis white cells will, adhere ("trap") to the endothelium of the capillaries as
result of venous hypertension, inducing the release of proteolytic enzymes and
superoxyde metabolites causing destruction of the tissue.*"*' This trapping seems
to be a nonimmunological phenomenon, due to low flow in the wide capillaries, as
no upregulation of binding molecules like ICAM, VCAM and ELAM is seen.*^
Microthrombi
The microthrombosis theory of Bollinger is based on studies by capillary
microscopy in patients with severe CVI and especially AB. Bollinger suggested
that AB is a result of minor skin infarctions caused by microthrombi.''5.*3
Microthrombi may develop as result of disturbance in coagulation or fibrinolysis.
Coagulation is characterised by the formation of fibrinogen into fibrin [figure 2].
FIGURE 2
Schedule of coagulation cascade.
TF = tissue factor
TFPI = tissue factor plasminogen inhibitor
VII, VIII and IX = coagulation factor VII, VIII and IX
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Fibrinolysis is performed by plasmin after activation by tissue plasminogen
activator, urokinase or neutral proteases [figure 3].**
Under normal physiological conditions, procoagulant and anticoagulant
mechanisms are delicately balanced. Disturbances may result in bleeding or
thromboembolic disorders. Several procoagulation factors have been studied,
suggesting a link between AB and disturbances in coagulation and fibrinolysis,
but up till now no suggestive conclusions can be made.
FIGURE 3
Schedule of fibrinolysis.
Plasma
(u-PA) ""•"*--*.
Plasminogen
Tissue
(t-PA)
r
Plasminogen •
activator
Plasmin
^ PA-inhibitors
ot2 antiplasmin
1
Fibrin • Fibrin degradation products
= activating
= inactivating
Endothelium
A defect of endothelial cell plasminogen activator in patients with AB was sug-
gested by Shornick ef fl/.'^ Studies on the defective release of tissue plasminogen
activator (t-PA) in patients with AB, however, did not prove a suppressed release
of t-PA, since at least 20% of the 118 control persons showed the same values as
patients with AB.'5.<* Also a high incidence of defective release of t-PA and
increased levels of PA-inhibitor and a high incidence of antiphospholipid anti-
bodies in patients with livedo vasculitis was reported by Klein.*'' Recently normal
t-PA levels were found in patients with CV1 and AB or dermatoliposclerosis.**
Increased levels of plasminogen activator inhibitor-1 antigen (PAI-1 antigen),
fibrinogen and F VIII, von Willebrand Factor and a decrease in coagulation rate
were found in a double blind study in 20 patients with venous ulcers compared
with twenty healthy controls suggesting a relative thrombocytosis and
hyperaggreability of platelets.*' The time of blood sampling of individual patients
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was not stated, however, which makes the results of PAI-1 less reliable since PAI-1
is subject to a diurnal fluctuation. Margolis e/ «/. found significantly increased
levels of PAI antigen in patients with CVI and dermatoliposclerosis, compared
with healthy controls.** Increased levels of PAI antigen were also found in patients
with CVI and AB, these were, however, not statistically significant. These data
suggest that patients with AB have moderately abnormal fibrinolysis, but in a
minor degree compared with patients with dermatoliposclerosis, who have
substantial tendency to abnormal fibrinolysis.
Increased values of PAI were also found in patients with Klinefelter's syndrome
and AB without venous insufficiency by Veraart e/ rt/.*
Platelets
Increased platelet aggregation was found in 7 patients with AB and livedo
vasculitis, in which antiplatelet therapy was successful.™ No control
measurements were done, however, and further studies to investigate the relation
between AB, CVI and abnormal platelet function were not performed.
Fibrin
An enhanced fibrin formation, as evidenced by elevated levels of total fibrin-
related antigen and D-dimer was suggested by Falanga ef n/."' In 6 of 11 patients
(55%) with venous disease with ulcers and in 3 out of seven patients (43%) with
venous disease without ulcers the values of D-dimer were increased. Although
these results are very suggestive of enhanced fibrin formation, the group studied
is very small. No difference is made in patients with CVI with or without AB.
Elevated levels of fibrinopeptide A in 6 patients with livedo vasculitis were found
by McCalmont <>/ n/." Unfortunately no control group was studied.
Autoantibodies
The presence of AB in patients with systemic disease without CVI, also suggest a
role of (local) coagulation disorders. For instance in patients with SLE, increased
levels of antiphospholipid antibodies, such as lupus anticoagulants and anti-
cardiolipines antibodies are seen.^^ The presence of antiphospholipid antibodies
suggests a thrombotic risk, whereas lupus anticoagulants antibodies are associated
with a higher thrombotic risk than anticardiolipines antibodies. The relation
between major thrombosis, as in deep venous thrombosis, and microthrombi
remains unclear. AB or livedo vasculitis has been described in two patients with
anticardiolipin syndrome/'' Recently, in a group of twelve patients with AB, anti-
cardiolipines antibodies were detected in two patients, abnormal levels of
circulating immune complexes were found in three patients, and two patients
showed anti nuclear antibody (ANA) positivity.^ The results were statistically not
significant. In 4 of 6 patients with AB studied by Klein anticardiolipines antibodies
were present, 2 of these patients showed a history of deep venous thrombosis.'"''
The percentage of overall thrombotic events in patients with SLE is 42% in
antiphospholipid antibodies positive and 13% in antiphospholipid antibodies
negative patients. The presence of antiphospholipid antibodies, however, may
only represent a marker of a prothrombotic state, rather than a risk factor for the
development of thrombosis.'"'
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Essential cryoglobulinaemia was seen in 4 of 27 patients with AB, which was not
related to CVI.*>
Vasculitis
Some authors suggest a primary vasculitis as the underlying factor because of
deposits of immunoreactants found in dermal blood vessel walls.*-'"-" The role of
immunologic factors in the development of AB is, however, unproved. Bard and
Winkelmann believed that AB represented one phase of segmental hyalinizing
vasculitis." The importance of immunological factors in pathogenesis was stressed
by Schroeter ef a/, who found positive immunofluorescence for complement
factors and immunoglobulines in the superficial, mid-dermal and deep dermal
vessels in a group of 15 patients with segmental hyalinizing vasculitis." Revie-
wing the data of Schroeter and Winkelmann, however, there was no true vasculitis
according to the international criteria of a leucocytoclastic vasculitis.'S-?-' It is more
likely that the immunological factors in the pathogenesis of AB are a secondary
phenomenon.™-^-^ This mechanism may be comparable with CVI, where a
moderate to strong expression of ELAM-1 is seen under venous leg ulcers."
Infection
Milian and Gonin described AB in patients with syphilis, and tuberculosis,
suggesting a chronic infection as cause for AB; however, this theory was never
proved and seems now most unlikely.n.80-82 The most likely explanation is that
due to a high incidence of tuberculosis at that time, the incidence of AB seemed to
be increased in patients with tuberculosis.
It is concluded that no studies can demonstrate increased fibrin formation, decre-
ased fibrinolysis or vasculitis as cause for AB. Some studies are suggestive of
thrombotic vasculopathy. Especially studies performed by Bollinger and co-
workers with a capillary microscope strongly sustain the theory of microthrom-
bj.45,83,84 Thus, both CVI and systemic internal diseases might induce local coagula-
tion disorders and impaired fibrinolysis, causing microthrombi, partly based on
diminishing flow in the capillaries as result of CVI, partly by yet unknown
mechanisms. It is suggested that in patients with CVI a decreased flow in capil-
laries may lead to increased sludge formation and cause increased coagulation
which finally results in microthrombi [figure 4]. Further studies in this field are
necessary.
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FIGURE 4
Hypothesis of aetiology atrophie blanche.
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HISTOPATHOLOGY
Data on histopathology are probably limited by the delayed healing that may
follow biopsy. The choice of the biopsy site is important. Some findings are based
on biopsies from the edge of ulcers, which differ from biopsies from fully
developed AB lesions, causing many misconceptions in comparing unequal
material.
Light microscopy
Light microscopy of a fully developed AB lesion is characterised by a thin and
flattened epidermis with local parakeratosis and focal spongiosis and varying
melanin deposition in the basal layer depending on the clinical hyper- or
hypopigmentationA26-77'79-*5-88 y^e dermis is thickened and sclerotic with
disappearance of the papillae.™^ This causes a scleroderma-like appearance.
The most pronounced abnormalities are found in the vessels of mainly the
superficial dermis [figure 5]. The capillaries are dilated and show tortuous loops.
Most vessels (capillaries and arterioles) show endothelial proliferation and are
thickened and swollen .539,79,85,89.90 Some vessels are occluded with fibrinoid mate-
rial or erythrocytes.™^ Sometimes extravasation of erythrocytes with hemosiderin
deposition is seen.™-*? Occasionally entire vessels are replaced by fibrinoid ma-
terial.^
Abnormalities of the vessels are seen both in the upper, middle and lower part of
the dermis.5.12.87 Perivascular a leucocytic or lymfohistiocytic infiltrate is seen of
variable intensity, but never outspoken. The small number of polymorphonuclear
leucocytes and the lack of nuclear fragments around the small vessels are the most
important signs to differentiate between AB and leucocytoclastic vasculitis.
When ulceration occurs, histology is similar to venous ulcers, except that the
epidermal necrosis is sharply defined, but bordered by hyperkeratosis and
acanthosis.'s In ulcerating AB lesions, a band of IgG, IgM and C3 can be seen
around vessels.'-™ These are the same vessel walls that show hyalinization in the
hematoxylin-eosine sections. The immune deposits form a continuous outline of
these thickened walls, with little or no deposition in the surrounding dermis. In
early lesions only fibrin depositions are seen, without immunoglobulin or
complement deposition. Some authors consider nonspecific staining as negative
immuno-fluorescence since no typical granular immunofluorescence staining
pattern is seen.^ Antigen-antibody complexes are not the most important factor in
the pathogenesis of AB, in contrast to leucocytoclastic vasculitis.n'5.88
Fibrin is deposited in linear layers around capillaries. Deeper in the dermis these
fibrin cuffs disappear. Different markers for fibrin and fibrinogen have shown
clear deposition of fibrin, but not of fibrinogen.'"
Electron microscopy
Electron microscopy shows dilatation of capillaries (with a diameter up to 100 urn)
with a thin endothelium, together with obliterated capillaries.^ The vessels are
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situated in a dense, fibrotic connective tissue. Fibrin deposition with occlusion of
the lumina of superficial blood vessels has been described."" Erythrocytes and
platelets are described trapped within the fibrin.*'* In older lesions endothelial cells
are replaced by heavy fibrin depositions.™'^
The pericapillary space is oedematous and contains extravasated erythrocytes and
macrophages."'' Shornick ef a/, did not see any inflammatory cells near the vessel
walls.''' Leu ef a/, noticed occasional lymphocytes and plasmocytes, but no
granulocytes.^ Zabel and Hettewer, however, described an infiltrate in which
both granulocytes, lymphocytes, plasmocytes, granulocytes and macrophages are
seen.™
It can be concluded that the most important histological abnormality are the dila-
ted capillaries which show tortuous loops and are partly occluded by fibrinoid.
Immunofluorescence staining can be considered as a non-specific finding.
FIGURE 5
Histology of atrophie blanche (lOOx); a flattened epidermis and tortuous
capillaries which are partly occluded.
MICROCIRCULATION
Microcirculation can be studied with capillary microscopy, transcutaneous oxygen
measurements (TcPCh), laser Doppler flowmetry (LDF) laser Doppler perfusion
imaging (LDPI) and microlymphography.
Capillary microscopy and TcPCh
Investigations by capillary microscopy give a good impression of the morphology
of the capillaries. In healthy skin capillary microscopy shows a regular pattern of
small capillaries.** In AB lesions an (almost) avascular field with no recognisable
capillaries is seen in the center.^.^ A capillary density of zero to less than 10/mm^
is measured in these areas.^^At the edge enlarged capillaries are visible lying ap-
proximately parallel to the skin surface, very characteristic of AB. The more
remote capillaries show a less altered morphology. This pattern is compatible with
that of CVI disturbances without AB.«
With intravenous bolus injection of Na-fluorescein a more functional aspect of
microcirculation is obtained.^^^5 ],-, the border of AB lesions the dye arrives in
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the same time as in healthy controls (ca 30 s). The dye reaches the centre of the
avascular lesion of AB only after 40 minutes.**
Transcutaneous oxygen measurements show TcPCb values close to 0 mmHg. In
border zones of AB the mean TcPC>2 reaches 24.0 mmHg, compared with 56.8
mmHg in control subjects.™ TcPC>2 values in patients with CVI without AB differ
significantly from healthy persons, dependent on stage of CVI.
Laser Doppler flowmetry and laser Doppler perfusion imager
Laser Doppler flowmetry (LDF) and laser Doppler perfusion imager (LDPI)
measure the flux in nutritive and thermoregulatory capillaries of the dermis.
Measurements show an increased median basic resting flux in patients with CVI
and AB lesions compared with normal skin.*-'" Venous hypertension, induced by
a upper thigh cuff, results in a similar decrease of flux in AB lesions or normal skin
(46% in normal, 56% in AB lesions).""
Lymphography
Microlymphography is performed with FITC-dextran, which is injected
subepidermally. In normal skin a regular, intact network of hexagonally shaped
meshes is seen.'"""" In patients with severe stages of CVI, the lymphatic capillary
network at the medial ankle is fragmented and destroyed, and the permeability of
the remaining microlymphatics is increased.'"-!""-'"* jn some patients dermal
backflow (cutaneous reflux) is described.'"* In patients with AB an abnormal
lymphatic flow was seen by Partsch.™
Technetium scanning
In differentiating AB from Kaposi's sarcoma and pseudo-Kaposisarcoma,
radionuclide scanning can be used. *>>nTc scanning is positive in cases of (pseudo)-
Kaposi sarcoma and negative in patients with AB.'"*
THERAPY
As AB was initially described as a consequence of syphilis, Milian advised
antisyphilitic therapy. After this theory had been abandoned, many other
therapies were used. There are as many theories described as there are
practitioners treating AB.™' Different surgical therapies have been used in the past
such as galvanocautery, sympathectomy, excision /« toto and paratibial fascio-
tomy, with no or only temporary relief.^ *-"®-"*' jhg ygg of X-ray is described,
which is now obsolete.-'* Systemic corticosteroids and topical steroids as well as
intralesional injections of lidocain and triamcinolone give poor results.**-*"-""-"''
Treatment with acyclovir is described in a case report.'" All above-mentioned
therapies are, however, almost all case-reports, and their therapeutic effect is
doubtful. Good clinical trials (prospective, randomised, placebo controlled) which
fulfil the Cochrane criteria are not found in literature.'"
As CVI is seen in about 99% of the patients with AB, therapy should be focused on
this aspect. Before therapy is started the presence of CVI must be determined.
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TABLE 2
Different therapies used in
Medicine
Phenformin
Ethylestrenol
Phenformin
Ethylestrenol
tPA
tPA Aspirin
Warfarine
Aspirin
Dipyridamolee
Ticlopidine
Aspirin
Dipyridamolee
Aspirin
Dipyridamole
Aspirin
Dipyridamole
Phenidine
Aspirin
Dipyridamole
Heparin sodium
Heparin sodium
Heparin sodium
Heparin sodium
LMWH (Nadro-
parin calcium)
Prostaglandin Ei
Lipoprosta-
glandin Et
Nifedipine
Sulfasalazine
Sulfasalazine
Pentoxifylline
Pentoxifylline
Pentoxifylline
Aspirin
Dipyridamole
Dose
50 mg Ixdd2
mg 2xdd
not stated
10 mg
10 mg, 81mg
2 to 4 mg
82 mg lxdd
225 mg lxdd
200 mg lxdd
325 mg 3xdd
75 mg 4x dd
325 mg 2xdd
50 mg 3xdd
365 mg lxdd
75 mg lxdd
150 mg lxdd
50 mg 3xdd
5000 IE 2xdd
5000 IE 2xdd
5000 IE 2xdd
12300 IE 2xdd
10 ng/kg
2hrs/day
10 ug
10-20 mg
3xdd
1 gr3xdd
500 mg 3xdd
400 mg 3xdd
400 mg 3xdd
400 mg 3xdd
300 mg lxdd
500 mg 3xdd
AB lesions
N
5
10
2
4
2
7
2
8
1
27
15
1
1
4
I
1
1
2
8
6
8
3
Success
rate
100%
100%
100%
100%
86%
100%
100%
100%?
48%
70%
100%
100%
improve
d
100%
100%
100%
100%
87.5%
improve
d
80%
67%
Length of
therapy
4 months
4-8 weeks
2 weeks
2 weeks
45 days
2-11
months
4 weeks
not stated
3 years
8 weeks
8 weeks
3 months
1 week
20 days
20 days
14 days
3 months
3 months
8 weeks
9 weeks
+ MT
3-11
months
2-7
months
Mechanism
Fibrinolysis and
increased tPA
activity
Fibrinolysis and
increased tPA
activity
Fibrinolysis
Fibrinolysis
Anti-platelet
aggregating
Anti-platelet
aggregating
Anti-platelet
aggregating
Anti-platelet
aggregating
Anticoagulant
Not in discussion
Not in discussion
Anticoagulant
Anticoagulant
Anticoagulant,
fibrinolysis
vasodilatation,
anti-platelet
aggregating
vasodilatation,
anti-platelet
aggregating
vasodilatory
effect
unclear
Inflammatory
immunologic,
platelets
Bloodviscosity
Blood viscosity
erythrocyte
flexibility
Bloodviscosity
erythrocyte
flexibility
Author
Gilliam"
Shornickn
Klein**
Klein"
Yamoto"'
Drucker **
Kern™
Elisaf™
Champio
1,122
Yang"
Yang"
Jetton-"
Heine »
Gunier'^
Uchida"'
Nonaka'*
Purceipa-
Gupta '"
Bisalburra
128
Sauer'»
Sams™
Sams'-™
Com
ments
1,2
1,2
1,2
3
3
1,2
3
1,2
3
1,2
1,2
3
2,3
1,2
2,3
2,3
2,3
2,3
1,2
1,2
1,2,4
1,2,4
N= number of patients
LMWH= Low molecular weight heparins
MT= maintenance therapy
1= not placebo controlled
2= based on clinical improvement
3= case-report
4= new ulcers during therapy
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The use of adequate compression therapy is essential and is still the cornerstone in
the treatment of venous disease.^-suiJ-ns -p^ maintain a situation of oedema
reduction, medical compression stockings should be prescribed.'" AB is clinically
found to be partially reversible after treatment with well adapted elastic support -
(compression)."* In cases of superficial venous insufficiency, treatment of the
veins can be considered, for example by means of sclerocompression therapy of
veins proximal and distal of AB lesion, as described by Tazelaar."-"?'"^
As impaired haemostasis and fibrinolysis may play an important role in aetiology,
therapy should modulate or interfere with microcirculatory disturbances [table 2].
Three major groups of drugs are used in the treatment of AB:
Drugs stimulating endogenous fibrinolytic activity
The combination of phenformin and ethylestrenol enhances endogenous blood
fibrinolytic activity by increasing plasminogen activating enzymes.'^ Gilliam ef a/,
have reported good clinical results with these two drugs in treating AB ulcers." In
1977 phenformin was removed from the general market by FDA decision because
of its side-effects. Since ethylestrenol alone is not effective, other drugs are sugge-
sted to use as a substitute for phenformin and ethylestrenol, such as low dose
tissue plasminogen activator (t-PA).^ Most results described are case reports.
Klein treated 2 patients with t-PA, during two weeks and 4 patients with t-PA and
aspirin and warfarin.*'' In some patients TcPCh improved during treatment and all
patients improved clinically. t-PA is introduced commercially as a specific fibri-
nolytic factor, lysing thrombi so its therapeutical effect on AB can be studied.
Drugs inhibiting thrombus formation (antiplatelet and anticoagulant)
Aspirin and dipyridamole are used by different authors, with both good and poor
clinical and subjective improvements.^'""™"'-121 Aspirin is a cyclooxygenase inhi-
bitor that suppresses thromboxane A2 and prostaglandin h. '^ A good double-
blind, randomised study, placebo controlled, with aspirin was made by Ibbotson
ef a/, in patients with venous ulcers in which an increased rate of ulcer healing was
seen in the aspirin-treated group.*"' dipyridamole inhibits synthesis of
thromboxane A2, and stimulates release of prostaglandin I2.™ Intravenous ad-
ministration of prostaglandin Ei has been described because it has vasodilator,
platelet aggregation inhibiting and erythrocyte deforming properties.'**.^
Pentoxyfylline has been used because of its improving effect on erythrocytes
deformability and lowering effect on blood viscosity.'^'''* Both aspirin and
pentoxyfylline have, besides the above mentioned properties, a positive effect on
rheology and prevent sludge formation. Anticoagulants have been first suggested
in 1962J22 Jetton and Heine used minidoses of heparin.^-so Heparin does not only
inactivate the coagulation cascade, it also decreases blood viscosity and increases
fibrinolytic activity.-'*''!*'^ Promising results with low molecular heparins were
described by Gunier, who reported rapid pain relief and cessation of the necrotic
process and tissue regeneration in 4 patients.'^
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Vasodilatating drugs
Purcell report the use of nifedipine.'^ Recently, Gupta has reported good clinical
effect with sulfasalazine, which is confirmed in 8 other patientsJ27428 yhg
mechanism of sulfasalazine is unclear. It might have an antiinflammatory and a
thromboxane inhibiting effect.
Best choice of drug
The first choice of treatment for AB ulcers in patients with CVI remains, however,
compression therapy. Reviewing above-mentioned studies, the most promising
effects in slow healing ulcers might be expected from heparin, aspirin and
dipyridamole.
CONCLUSION
Atrophie blanche cans clinically be divided into a segmented and a plaque form,
as performed by Milian did in 1929.1 jp daily practice this classification is not
useful, since both forms are seen in association with different diseases. It is
however important to make a difference whether AB belongs to the complex of
symptoms of CVI, which is mostly the case, or whether AB is the result of systemic
diseases. A clinical and technical workup for venous diseases should always be
performed."* Certain aspects should be considered, reviewing the different
morphologic descriptions of AB. When AB is described with systemic disorders,
atrophy is seen, but hyperpigmentation and teleangiectatic capillaries are not
described, and are not found in histopathology. It is not always clear whether
these disorders only resemble AB, and are in fact only scars."?-™ Originally
Milian described that AB could be mistaken for a scar, but probably a scar also can
be mistaken for AB. Especially AB segmentaire cannot clearly differentiated from
other atrophies. So, only when a combination of one or several white, smooth, de-
pressed, ivory white plaques of variable dimensions, surrounded by a small pig-
mented ring in and around which numerous teleangiectatic capillaries are arrayed,
can the diagnosis AB be made.
In almost all cases of histology of AB obstruction of small vessels is described,
sometimes these are found predominantly in the upper dermis, sometimes
predominantly in the lower dermis. The term livedo vasculitis and other
synonyms should be avoided. In the future it is advised to use the term atrophie
blanche instead of livedo vasculitis.
The presence of avascular fields in AB lesions may be caused by a combination of
microthrombosis causing microinfarctions, impaired haemostasis and fibrinolysis
and endothelial damage. Trapping of leucocytes may also cause microvascular
occlusion, reducing the number of functional capillaries.
AB can develop after ulceration or can be a <fr HOZ>O phenomenon. It is
hypothesised that local dysregulation of coagulation and impaired fibrinolysis are
most important in the pathogenesis. Inflammation is only a secondary
phenomenon. Different disorders such as CVI and several systemic diseases might
function as a trigger for this dysregulation.
In patients with AB, especially in the area between the knee and the ankle (gaiter
area), a phlebological analysis is indicated to diagnose or exclude CVI. If CVI is
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excluded, or the lesions are located elsewhere than in the medial ankle region area,
further investigations for internal diseases are indicated. In some cases, when
further investigations show no abnormalities, AB can be seen as a idiopathic
disease.
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SUMMARY
Atrophie blanche is a characteristic cutaneous disorder, which can be considered
as belonging to the complete syndrome of chronic venous insufficiency. The
prevalence is not clear. We studied a group of 126 patients (151 legs), presenting
with a leg ulcer in an outpatient clinic in the south of the Netherlands. In 31% of
the male patients and 44% of the female patients atrophie blanche was part of the
clinical symptomatology of chronic venous insufficiency. This is a higher
prevalence than reported in the literature. Patients with atrophie blanche showed
significantly more recurrent ulcers than patients without atrophie blanche.
Aetiology of atrophie blanche is still unclear. One of the most important theories is
that a disturbed microcirculation as result of chronic venous insufficiency leads to
microthrombi and local occlusions of the vessels. Patients with atrophie blanche
are seen more often in out patient clinics specialised in phlebology. Ulcers of
atrophie blanche form a select group of ulcers in patients with chronic venous
insufficiency with a high risk for recurrences.
RESUME
L'atrophie blanche (AB) est une anomalie caracteristique de la peau est consideree
surtout en Europe, comme faisant partie integrante du syndrome de I'insuffisance
veineuse chronique (IVC). Ses repercussions restent obscures.
Nous avons etudte un groupe de 126 patients (151 jambes) qui se sont presented
atteints d'ulcus cruris dans un service de dermatologie du Sud des Pays-Bas.
Chez 31% des hommes et 44% des femmes, TAB ne represente qu'une partie de la
symptomatologie de 1'IVC mais en realite ces repercussions sont plus importantes
qu'on ne le d6crit dans la literature. Dans le groupe de patients atteints d'AB, il
6tait tres souvent question d'une recidive d'ulcus cruris. L'ethiologie de TAB est
encore incertaine. L'une des theories les plus reconnues admet que 1'IVC provoque
une pertubation de la microcirculation, des microthromboses sources d'occlusions
veineuses locales. Compte tenu de la gravite des repercurssions, les patients
atteints d'une AB ulceree sont hospitalises dans un service specialise en
phlebologie. Les AB ulcerees constituent un groupe d'ulceres propice aux
recidives.
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INTRODUCTION
Atrophie blanche (AB) belongs to the complex of symptoms of chronic venous
insufficiency (CVI) and is often seen in patients with recurrent leg ulcers. Leg
ulcers in patients with atrophie blanche are characterised by severe pain and slow
wound healing.
Besides CVI, atrophie blanche is seen in patients with lupus erythematodus,
scleroderma, cryoglobulinaemia, thallassemia and Klinefelter's syndrome [table
1J.2-*
The frenchmen Milian was the first to introduce the term atrophie blanche for
smooth, depressed, ivory white disorders with dilated capillaries, which are
mainly located on the distal part of the Ieg7 His original hypothesis that atrophie
blanche was caused by "TVeponenw P<j//idum" was never proved. Since that time,
several hypothesis about the aetiology of atrophie blanche have been raised. The
most accepted theory is that atrophie blanche is part of CVI.*' As a result of
microthrombi, occlusion of capillaries is seen, leading to local dermal disorders,
such as atrophie blanche.
TABLE 1
Atrophie blanche is associated with several disorders.
Disorder
Thalassemia minor
Cryoglobulinemia
Systemic lupus erythematodus
Scleroderma
Klinefelter's syndrome
Author
Berge (3)
Ryan (4)
Ryan (4) Bard (5)
Ryan (4) Bard (5)
Veraart (7)
Stevanovic (6)
Stevanovic (6)
Atrophie blanche is defined as smooth, depressed, ivory white plaque of variable
dimensions, surrounded by a small pigmented ring of several millimetres in
width, around which numerous teleangiectatic capillaries are arrayed. Atrophie
blanche is mainly located on the medial or lateral malleolus. Besides the malleolus,
atrophie blanche is seen on the dorsal side of the foot and pretiabial. Atrophie
blanche is seldom seen on other parts of the body. If atrophie blanche is located on
other parts than the leg, it is mostly associated with internal diseases. Milian
originally distinquished two forms of atrophie blanche: "atrophie blanche en
plaque" and "atrophie blanche segmentaire". The last is hard to differentiate from
a scar.
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According to the classification from Widmer, atrophie blanche belongs to stage
two of CVI.'° In a study of Van der Molen in 1953, only 9% of the patients with a
leg ulcer suffered from atrophie blanche." This is a small percentage, considering
that atrophie blanche forms a symptom of CVI. Prevalence between 11% and 37%
is found in several studies by both dermatologists and surgeons.'^-is Because it is
still unclear how often atrophie blanche is seen in patients with recurrent leg
ulcers, and since recurrent leg ulcers forms a large socio-economic problem, we
studied the prevalence of atrophie blanche in patients with (recurrent) leg ulcers .
METHODS
All patients visiting the phlebological outpatient clinic of the Sint Joseph hospital
for a venous leg ulcer in the period between 1-1-1990 and 30-6-1994 were included.
Patients were asked whether they suffered from diabetes mellitus, arterial diseases
and autoimmune diseases. Phlebological examination was done clinically: the
presence of corona phlebectatica, dermatoliposclerosis and atrophie blanche was
noted. Additional investigations to measure ankle/arm index and venous reflux
(with digital photoplethysmography) were done if necessary.
RESULTS
In this period 126 patients were seen, of which 25 had a leg ulcer on both legs.
Totally 151 legs were seen with a leg ulcer, 82 with an ulcer on the left leg and 69
on the right leg. Thirty five men were seen and 91 women with an average age of
68.2 years (24-93). The average age of the women was, 70.0 years, which was
significant older than the average age of the men (63.4 years, p=0.02).
Atrophie blanche was seen in 31% of the men and in 44% of the women, this
difference was, however, not statistically significant [table 2].
During this period, 30 of the 126 patients (24%) developed recurrent leg ulcers. In
total recurrent leg ulcers were seen in 52 legs (34%), 34 times at the left leg and 18
times at the right leg. Recurrent leg ulcers were more often seen in atrophie
blanche lesions, 37 times (71%), this difference is statistically significant (p=0.0004).
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TABLE 2
126 patients with leg ulcers.
Number of patients
Mean age
Number of leg ulcers
Ulcer located left/right leg
Recurrent leg ulcer without AB
Recurrent leg ulcer with AB
Number of patients with AB
Average age of patients with AB
AB left leg
right leg
both legs
Men
35
63.4 years
40
23 / 17
4 (11%)
8 (23%)
11 (31%)
55.3 years
10
1
0
Women
91
70.0 years
111
59 / 52
11 (12%)
29 (32%)
40 (44%)
67.6 years
22
13
5
P value
/> = 0.02
NS
NS
NS
NS
p = 0.04
AB: Atrophie blanche
NS = not significant
In the last two years, 25 patients were seen with atrophie blanche, 15 with atrophie
blanche on one leg and 10 with atrophie blanche on both legs. This group of
patients consisted out of 6 men and 19 women [table 3]. Atrophie blanche was
seen in 9 patients on 1 location, in 9 patients on 2 locations, in 2 patients on 3
locations, in 4 patients on 4 locations and in 1 patient on 5 locations. In this group
of patients, 25 suffered from mild hypertension, 2 patients suffered from diabetes
mellitus and 2 patients suffered from arterial insufficiency. Non of the patients
had autoimmune disorders or cryoglubinemia.
Only one patients noticed an increase of complaints during the summer and a
decrease during the winter. Other disorders consisted of arthrosis of the hip (1
time), cardiovascular accident (1 time) and decompensatio cordis (1 time).
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TABLE 3
Location of atrophie blanche in 25 patients.
Location
Left medial malleolus
Left lateral malleolus
Pretibial left
Right medial malleolus
Right lateral malleolus
Right leg: pretibial
dorsal side of feet
Number of patients
23 (92%)
11 (44%)
2 (8%)
10 (40%)
6 (24%)
1 (4%)
1 (4%)
DISCUSSION
Our results only partly confirm the results of Metz, who described that atrophie
blanche was mainly seen in middle aged women." Men with atrophie blanche
were seen in 31% in our group of patients with atrophie blanche, while Metz only
described 5-10%. No patient under the age of 27 was seen.
The prevalence of atrophie blanche in patients with an active leg ulcer in this
study is very high (40%) and has not been described before. Only two times
atrophie blanche is described in around 30% of patients with CVI.'*-" This high
prevalence may be explained by the slow healing tendency of leg ulcers in
atrophie blanche. In the Netherlands most patients with a venous leg ulcer are
treated by a family doctor. Only when he does not succeed, patients are sent to an
outpatient clinic. As a result the group of patients seen in an outpatient clinic are a
selected group of patients, these are more often patients with slow healing leg
ulcers.
The pathogenesis of atrophie blanche is still unclear. The hypothesis of Milian that
atrophie blanche is the result of "Treponemfl Pa/Z/difm" has been abonded/ In the
fifties it was already suggested that atrophie blanche is the result of CVI and
varicosis.H'17 Other authors suggest that atrophie blanche is the result of vasculitis.
2,18-20 Stevanovic hypothesised that atrophie blanche is the result of occlusion of
small vessels in the skin.' Shornick divided atrophie blanche into a primary and
secondary formal Primary atrophie blanche is the result of a vasculopathy, which
is associated with a decrease of plasminogen activator, while the secondary form
is related to autoimmune diseases.^ At this moment the most accepted theory is
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that atrophie blanche is the result of CVI. As a result of a diminished capillary
flow, microthrombi develop, which results in small infarct of the skin."
Obliteration of some of these small vessels result in a vascular areas, such as
atrophie blanche.
Histopathology of atrophie blanche is characterised by tortuous capillaries, which
sometimes are replaced by fibrinoid material. The decreased number of capillaries
was confirmed by capillary microscopy by Bollinger ef <J/. *-^  They found avascular
areas in atrophie blanched
It is unclear why not all patients with CVI develop AB. We hypothesise that as a
result of retrograde flow, the venous pressure and capillary pressure increases,
resulting in venectasia with a decreased flow [figure 1]. Sludge formation, white
cell trapping and fibrinolytic disorders will finally result in AB. It is most likely
that in the fibrinolytic disorders especially local processes are involved.^ Increased
levels of plasminogen activator inhibitor support this theory.'' Also the increased
concentration of fibrinopeptide A, a symptom of increased thombogenic state, is
suggestive for a role coagulation disorders in AB.^
Several therapies for the treatment of venous leg ulcers with and without AB are
described. Besides compression therapy, case report with the use of heparins,
dipyridamole, aspirin and salazopyrine are described, with varying results.^s-^
The recurrence of leg ulcers in the group of patients in this study can be explained
by non-compliance behaviour of the patients. Especially continuous compression
therapy is for a lot of patients very difficult. Another reason might be the presence
of coagulation disorder in patients with AB.
It is very likely that in patients with AB, besides increased venous pressure, local
fibrinolytic disorders play an important role in pathogenesis. Treatment with
compression therapy and anticoagulant therapy or fibrinolytic therapy would be
necessary to prevent recurrent ulcers. Further studies are necessary to assess the
decrease of the recurrence rate in patients with AB.
It is concluded that in patients with long lasting CVI, decompensation of CVI
occurs, resulting in recurrent leg ulcers and an increase in prevalence of AB. Since
ulcers in AB show a slow tendency of healing, adequate compression therapy in
an early stage seems important to prevent the recurrence of leg ulcers in this area.
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FIGURE 1
Hypothesis of aetiology atrophie blanche.
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CHAPTER 4
CHANGES IN MICROCIRCULATION IN PATIENTS WITH ATROPHIE
BLANCHE VISUALIZED BY LASER DOPPLER PERFUSION IMAGING
AND TRANSCUTANEOUS OXYGEN MEASUREMENTS
M.B. Maessen-Visch MD, A. Sommer MD, J.A. De Paepe,
H. A.M. Neumann MD PhD
Phlebology 1998; 13:45-49
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ABSTRACT
Objective
To quantify differences in microcirculation in atrophie blanche (AB) in patients
with chronic venous insufficiency (CVI) and in healthy controls before and after
venous occlusion.
Design
Prospective study in a single patient group. > ••-. -
Setting
Department of Dermatology, University Hospital Maastricht, the Netherlands.
Patients and methods
16 patients with CVI and large lesions of AB, 10 patients with CVI without AB and
10 healthy controls were enrolled in the study. Laser Doppler Perfusion Imaging
(LDPI) measurements were performed in and outside large lesions of AB and in
healthy controls. Transcutaneous oxygen (TcPCh) measurements were performed
in patients with CVI with and without AB and in healthy controls.
Results
Median basic resting flow was higher in AB than in healthy controls (0.67 mV
versus 0.21 mV, p=0.002). The venoarteriolar response(VAR) was increased
significantly in AB (58% versus 43%, p=0.04). A significant decrease in TcPCh
values occurred in AB lesions with 40 mmHg, in CVI skin with 60 mmHg and in
healthy controls with 80 mmHg artificially induced venous pressure.
Conclusion
Basic resting flux in AB measured with LDPI is increased compared with clinically
normal skin. The decrease in flux on venous occlusion is larger in AB than in
healthy controls.
Key words: white atrophy, laser doppler perfusion imager, venoarteriolar respon-
se
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INTRODUCTION
Atrophie Blanche (AB) is a clinical disorder often seen by dermatologists and
phlebologists. AB is described in scleroderma, systemic lupus erythematodus and
cryoglobulinaemia.i--' Most AB lesions seen in patients, however, are a result of
chronic venous insufficiency (CVI).*-* In 10 - 30% of patients with CVI, AB is
seen.*-'"
CVI is a complex of symptoms caused by venous reflux, due to valvular
incompetence of deep, superficial and/or perforating veins, and leading to an
increased walking venous pressure. The increased venous pressure of the
macrocirculation is transmitted retrogradely into the microcirculation of the skin,
resulting in changed morphology of the capillaries. All well-known skin changes
in CVI are the result of the disturbed macro- and microcirculation.
In patients with AB, not only the morphology of capillaries is changed, but also
the number of capillaries is reduced and the capillaries are often obstructed."
Changes in microcirculation can be studied with transcutaneous oxygen measure-
ments (TCPCH)'-, capillary microscopy", laser doppler flowmetry (LDF)'-> and laser
doppler perfusion imaging (LDPI).'-» In the area of AB, values of TcPCh are
reduced, even to zero.'* Capillary microscopy in CVI, and especially in AB shows
dilated and elongated vessels with a winding, glomerulus-like appearance and an
increase in the pericapillary leakage diameter (halo)." LDF shows increased flux
in the skin of patients with CVI."'5-i8 Both a decreased vasoconstrictor response
on standing in patients with severe CVI^.i', as well as an unchanged
vasoconstrictor reaction in medium to severe CVI have been described.'''"' No
specific LDF measurements in AB are reported.
LDF, however, is limited in its clinical usefulness by its poor reproducibility.'"* The
main disadvantages are its spatial resolution (1 mm^), artefacts of movement and
the difficulty in applying the probe exactly and directly to the previously
measured tissue.'''
Recently LDPI has been developed to avoid the disadvantages of LDF and is
described as highly reproducible."-"-** LDPI measures perfusion of the skin in a
much larger area and yields an average value of 4096 points. There is no contact
between the scanner and the skin, so measurements do not influence the blood
flow. LDPI therefore has many advantages above LDF for assessment of
microvascular perfusion of the skin.20
The aim of this study was to determine alterations in flux and transcutaneous
oxygen values in AB lesions and healthy looking skin in patients with CVI before,
during and after venous occlusion. Decreased numbers of capillaries and arterioles
in AB lesions suggest an increased flux in AB lesions at rest and an altered
venoarteriolar response might be found. Our aim was to evaluate the flux in the
capillaries in AB.
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PATIENTS AND METHODS
P a t i e n t s rr»<"! ;•.?••-,•-:q'f j ^ . • ; . > .:••,.•
Group A: Sixteen patients (8 males, 8 females, average age 61 (32-80) years), with
CVI and AB plaque lesions at the medial ankle, larger than 2 x 2 cm.
Group B: 10 patients (5 male, 5 female, average age 65 (43-75) years) with CVI
without AB and dermatoliposclerosis.
Group C: ten healthy controls (5 males, 5 females, average age 53 (32-74) years).
CVI was defined as reflux in the superficial, deep and or perforating veins with
doppler/duplex ultrasound, decreased venous refilling time (<15 s) as measured
by light reflex rheography and by clinical symptoms of corona phlebectatica, AB
and dermatoliposclerosis. Exclusion criteria were arterial insufficiency, diabetes
and coagulation disorders. All CVI patients were well compensated and had been
wearing elastic compression stockings for at least the last six months. Three
patients were known with mild, well-controlled hypertension.
LDPI measurements were performed in AB lesions in group A, control
measurements were performed in the medial ankle region in group C and in the
knee region of group A.
TcPO2 measurements were performed in 9 AB lesions of group A and in adjacent
non-AB skin. Control measurements were performed at the medial ankle of
patients in group B and C.
The Ethics Committee of the University Hospital of Maastricht approved the
study.
Laser Doppler perfusion imager
In order to measure skin perfusion all measurements were performed with the
PIM.Lisca version 2.4 (Linkoping, Sweden). A full description of the Laser-
Doppler together with an evaluation of the laser-technique is given elsewhere.''' In
brief the instrument generates a colour-coded image of the spatial distribution of
tissue perfusion [figure 1]. The LDPI comprises a 2-mW helium-neon laser whose
beam is directed at the tissue via an optical scanner. This consists of two mirrors
controlled by two stepping motors, which sequentially measure up to 4096 points.
The back-scattered light is detected by a photo diode at a distance of about 15 to 20
cm from the tissue surface. An area of 40 cm* can be scanned. Each colour-coded
pixel represents approximately 1 mm' of tissue. The scanner is controlled by a
personal computer, which is also used for image display and storage. The images
are displayed with colours representing a scale of mean blood velocity.^
Transcutaneous oxygen measurements
TcPC>2 measurements were performed with the transcutaneous TCM 2
(Radiometer, Copenhagen, Denmark) as described previously.^' The TcPCh
electrodes were calibrated in room air. The probe temperature was set to 44°C.
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Procedure
Patients were placed on a couch in a comfortable supine position with the leg
being measured, in a stable, relaxed position. A pneumatic tourniquet (width 18
cm) was placed around the thigh of the leg being measured. The distance between
the measured skin and the LDPI was 20 cm. After an acclimatisation period of 15
minutes in a room with a constant temperature of 22 °C, measurements with LDPI
were performed in a completely darkened room.
TcPO2 measurements were performed under the same conditions, either 20
minutes after LDPI measurements or the next day.
FIGURE 1
Laser Doppler perfusion imager.
Venous occlusion test
The first LDPI measurement was performed in a square, measuring 36 mm x 36
mm in an almost complete AB lesion. The pneumatic tourniquet was inflated to 70
mmHg and measurements were performed after 2 and 5 minutes. The tourniquet
was deflated and the last measurement was performed 30 seconds after deflation.
Each measurement took 60 seconds.
Control measurements were performed in the middle of the medial side of knee at
the same limb in the healthy skin of 10 patients (group A) and in 10 healthy
control patients in the medial ankle region (group C). For all scans, the computer
calculated the mean perfusion in millivolts (mV) and the standard deviation (SD).
The venoarteriolar response (VAR) was defined as basic resting flux (BRF) minus
flux during venous occlusion (VOC) as a ratio to basic resting flux (100*(BRF-
VOC): BRF).
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For TcPO2 measurements the tourniquet was inflated after stabilisation was
reached (about 30 minutes). The tourniquet was inflated to 20, 40, 60 and 80
mmHg, for 5 minutes each.
Statistics
A Graphpad instat software package was used. Results were statistically compa-
red using Wilcoxon's paired signed rank test, or in the case of inter group
comparisons, the Mann-Whitney U test.
RESULTS
Table 1 shows details of the perfusion in millivolts in AB lesions, healthy skin in
CVI patients (knee region) and in healthy controls. Median basic resting flow was
significantly higher in areas with AB lesions than in healthy controls (0.67 mV
versus 0.21 mV p=0.002). Median basic resting flow was also significantly higher in
areas with AB lesions, than in control measurements in the knee region (0.67 mV
versus 0.31 mV, p=0.008).
TABLE 1
LDP1 measurements: mean (and median) perfusion in millivolts (mV) in Atrophie
Blanche (AB), healthy control patients and normal skin in knee region of patients
with CVI and AB before, during and direct after venous occlusion.
Number of patients
Before venous
occlusion
After 2min70
mmHg
After5min 70
mmHg
After venous
occlusion
AB lesions
16
0.67 (0.46)
0.25 (0.24)
0.27 (0.25)
0.67 (0.49)
Healthy control
patients
10
0.21 (0.20)
0.12(0.11)
0.11 (0.11)
0.19(0.20)
Normal skin in knee
CVI
10
0.31 (0.28)
0.19 (0.17)
0.19 (0.18)
033 (0.34)
Venous occlusion with 70 mmHg of two minutes, obtained by inflating the
tourniquet on the upper leg to 70 mmHg, resulted in a decrease of flux. There was
a significant difference between decrease in flux of AB lesions and normal skin
[table 1].
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TABLE 2
The venoarteriolar response (VAR): basic resting flux (BRF) minus flux during
venous occlusion (VOC) as ratio from basic resting flux (100*(BRF-VOC):BRF) and
the reduction in flux on venous occlusion (VOC/BRF) in AB, in normal skin
(knee region) in patients with AB, and in healthy controls.
VAR
VOC/BRF
Normal skin knee region
33%
p=0.003
67%
p=0.004
Atrophie Blanche
58%
42%
Healthy controls
43%
p=0.04
57%
p=0.03
P values, compared with AB lesions
The flux did not decrease further after 5 minutes of venous occlusion. Deflating
the cuff resulted in the same flux as before venous occlusion in both groups.
TcPO2 resting values were significantly lower in AB lesions [table 3]. TcPO2 resting
values were not significantly different in patients with CVI, perilesional
measurements and healthy controls. A significant decrease in TCPO2 values
compared with basic values occurred in AB lesions with 40 mmHg, in CVI skin
with 60 mmHg and in healthy controls with 80 mmHg.
TABLE 3
Average transcutaneous oxygen values (in mmHg) in AB lesions, perilesional skin,
CVI without AB lesions and healthy controls before, during and after venous
occlusion
Number of
patients
Resting values
20 mmHg
40 mmHg
60 mmHg
80 mmHg
After
AB lesions
9
10.6
9.4
7.4 *
5.1 *
4.4 *
7.4
Perilesional
9
58.3
57.7
56.3
53 *
46.9 *
53.3
CVI without
AB
10
62.4
58.9
58.6
55 *
47.3*
59.9
Healthy
controls
10
63.8
65.1
67.1
62.8
52.7*
67.7
- significant compared with resting values
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DISCUSSION
Capillary microscopy, TcPO2 measurements and LDI measurements'*^^ can
obtain information about the microcirculation. Recently, LDPI is added for
microcirculatory measurements." The technique of LDPI is able to produce a two-
dimensional image of the cutaneous microcirculation within a specific area and
does not influence the skin because there is no contact between the scanner and
the skin."^ Although AB is a severe complication of CVI, measurements with
LDPI performed specifically in AB lesions have not been reported before. Increa-
sed basic flux in patients with CVI in general or liposclerotic skin is described >M5-
'7, however nothing is known about AB.
In this study a significantly increased resting flux measured by LDPI has been
measured in areas with large AB lesions in patients with CVI, compared with
healthy controls (p=0.002, Mann Whitney test) and in clinical normal looking skin
in patients with CVI (p=0.008, Mann Whitney test).
An increased flux measured by LDI in patients with CVI has been described
previously." An increased resting flux in areas with AB lesions can be explained
by the morphology of AB. LDPI measures to a depth of 1-1.5 mm, where
capillaries, arterioles and venules are present. In AB lesions the number of
capillaries is decreased so the blood volume has to pass through a decreased
number of capillaries.^ When the number of moving erythrocytes is increased or
when the velocity of blood flow is increased, an increase of flux can be expected.
The same volume can only pass through a decreased capillary bed, when the
velocity is increased. So other capillaries, leading to an increased basic resting flux
perform the function of the occluded capillaries. In summary the increased flux
could represent a decreased number of capillaries, and an increase in flow and
diameter.
The increase in flux can not only be found in AB lesions but probably also around
AB lesions.
As expected significantly decreased TcPCh values in AB lesions were found.
TCPOT values in CVI patients (both perilesional skin and CVI patients without AB)
were decreased compared with healthy controls, although this difference was not
statistically significant. These data are consistent with other studies, which show
non-significantly decreased TcPCh values in patients with CVI without clinical
signs, whereas TcPCh values in patients with CVI with clinical signs are
significantly decreased. 12.16 In our study TcPCh measurements of patients with CVI
showed no clinical abnormalities: in perilesional measurements AB was avoided,
while in patients with CVI, there was only mild CVI, without
dermatoliposclerosis and AB.
The contradiction of increased flux and decreased TcPCh values in AB lesions can
be explained as follows. TcPCh values predominantly reflect the effects caused by
the capillaries (comprising a considerable part of the nutritive vessels), which are
partly occluded by microthrombi and might be influenced by fibrin cuffs, trapping
of leucocytes and oedema, whereas the LDPI mainly reflects the flux of blood in
the deeper skin layers (which mainly serve the thermoregulation). Chronic venous
hypertension may cause increased flux in the deep vessels, and because of
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vasodilatation a decreased flux in the superficial vessels, which increase the risk
for developing microthrombi. Bollinger suggests that AB is a result of minor skin
infarctions caused mainly by CVl.-* Decreased TcPCH values and decreased
numbers of capillaries in AB support this hypothesis. Other important theories
causing CVI play a role such as disturbed fibrin formation and "trapping" of leuco-
cytes are sustained by decreased flux.^-5
To simulate the high walking venous pressure, that exists in patients with CVI, a
venous occlusion test was used. A statistically significant difference in
venoarteriolar response, and so a difference in reduction in flux on venous
occlusion between AB and healthy skin was found. These data are consistent with
other studies, where both Leu ef a/.'^  and Creutzig ef n/> found a greater decrease
in flux on venous occlusion in CVI skin than in healthy controls. Belcaro ef n/.'s
described an impaired venoarteriolar response in CVI skin, while no difference
was measured in other s tudies . '^ Differences in results might be explained by the
different methods used. In most studies LDF is used instead of LDPI. LDF,
however, is limited in its clinical usefulness by its poor reproducibility.''' The main
disadvantages are its spatial resolution (1 mm-), and the need to apply the probe
directly to the tissue of interest." LDPI has a high reproducibility and records the
perfusion in a specific tissue area.^^
In addition to different techniques, a greater reduction in flux can be expected in
CVI patients, because their basic flux is much higher than in healthy controls.
In our study venous hypertension is produced in the supine position by inflating a
cuff around the limb, instead of standing position. This method is described by
Kuiper and Brakk£e and is of proven reliability^ and has been used in several
studies."-I?-*" Venous occlusion by a cuff applied to the thigh, results in equal
pressures in the veins, causing venous occlusion with an unchanged arterial
inflow.
In our study no rebound reaction after venous occlusion was seen in the LDPI
measurements, neither in CVI patients, nor in healthy controls. This might be
caused by the long duration of measurement (about 1 minute).
It can be concluded that basic resting flux in AB lesions measured with LDPI is
increased compared with clinically normal skin and healthy controls, and that the
flux is decreased more by venous occlusion in AB lesions. A strongly decreased
flux on venous occlusion might lead to an increased risk in coagulation disorders
of developing microthrombi and trapping of leucocytes, finally resulting in AB
lesions. Because there is no rebound reaction, a lack of reserve capacity of the
microcirculation is suggested.
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CHAPTER 5
THE INFLUENCE OF ARTIFICIALLY INDUCED VENOUS HYPERTENSION
ON CAPILLARY FLOW IN PATIENTS WITH CHRONIC VENOUS
INSUFFICIENCY WITH AND WITHOUT ATROPHIE BLANCHE
M.B. Maessen-Visch MD, J.C.J.M. Veraart PhD MD, A.J.H.M. Houben
H.A.M. Neumann MD PhD
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ABSTRACT
Chronic venous insufficiency (CVI) is known for its long term complications as a
result of increased walking venous pressure in macro and microcirculation.
Atrophie blanche is one of the most severe complications because of its recurrent
painful and difficult to heal leg ulcers.
With the use of capillary microscopy we performed a pilot study of the skin
microcirculation in atrophie blanche in the medial ankle region of 5 patients with
CVI without atrophie blanche. Patients were investigated in supine position.
During different venous hypertension pressure steps, induced by tourniquet
inflation, a decrease in capillary blood cell velocity was seen in both groups.
Venous hypertension was induced by a inflatable cuff around the thigh. There was
no difference in initial capillary blood cell velocity or in reaction pattern between
both groups.
Venous hypertension induced capillary flow stops or standstills; the number of
standstills and the total duration of standstill increased during venous pressure
steps. Long duration standstills were seen equally in both groups.
Although the efflorescencies of atrophie blanche and CVI without atrophie
blanche are dramatically different, the functional alterations, observed with the
capillary microscopy are the same. This suggest that different clinical signs of CVI
are based on the same basic alterations of the skin microcirculation in CVI. Local
factors may be responsible for the differences in skin manifestations in the cause of
CVI.
Standstills and decreasing capillary blood cell velocity are probably a normal
physiological reaction on venous hypertension. The importance of this
phenomenon in the pathogenisis of CVI is unknown. It is possible that they form
an increasing risk for the formation of microthrombi in patients with CVI, together
with the known endothelial damage in capillaries and white cell trapping.
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INTRODUCTION
Chronic venous insufficiency (CVI) is well known for its frequent complications of
atrophie blanche, dermato- et liposclerosis and recurrent long-standing leg ulcers.
As a result of venous reflux caused by valvular incompetence of deep, superficial
and/or perforating veins an increased walking venous pressure is obtained.' The
increased venous pressure in the macrocirculation is transmitted retrogradely into
the microcirculation of the skin, finally resulting in changed morphology of the
capillaries.'-^ Four major theories for developing skin complications and the
formation of venous leg ulcers have been put forward 1) the development of fibrin
cuffs around capillaries ', 2) intracapillary microthrombi*, 3) white cell trapping^,
and 4) the growth factor trap hypothesis.* In the fibrin cuff theory it is suggested
that leakage of fibrinogen from the capillaries induces a fibrin-cuff around the
capillaries, leading to a diffusion barrier for oxygen and nutrients. ' Bollinger
demonstrated by using capillary microscopy that there is a reduced number of
capillaries in CVI skin and suggested that this might be the result of
microthrombosis.'' In the hypothesis of white cell trapping it is suggested that, due
to venous hypertension, white cells adhere (trap) to the endothelium of the
capillaries which induces a release of proteolytic enzymes and superoxyde
metabolites, causing destruction of the surrounding tissue.' Finally, it is suggested
by Falanga that venous hypertension induces microtrauma of the endothelium,
which results in increased capillary permeability with leakage of fibrin and
macroglobulins into the dermis; these extravasated plasma proteins may trap
growth factors, leading to slowly healing ulcers.<• Neither of these theories have
been fully proven until now, although it is generally accepted that probably a
combination of these factors plays a role in the pathogenesis of complications of
venous insufficiency. It is clear that tissue viability is threatened when nutritional
circulation is7
Especially in atrophie blanche lesions in CVI, there are strong indications that
microthrombi occur in microcirculation. Both histological studies and capillary
microscopic studies support this theory. Histologically, occlusion of capillaries in
the papillary dermis is shown in atrophie blanche."'* Bollinger found avascular
fields and clear indications of minor skin infarctions using sodium fluorescein
capillary microscopy.''
Up to now the effect of venous hypertension on capillary flow was, to our
knowledge, only measured by Fagrell and Ostergren in the nailfold capillaries of
healthy individuals.™-" They measured both a decrease in capillary blood cell
velocity and standstills during venous hypertension. The effect of venous
hypertension on capillary flow in the medial ankle region of patients with CVI is
unknown. Atrophie blanche is always reported by clinicans as a severe sign of CVI
with a high risk factor for the development of painful and slowly healing leg
ulcers.
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It is unclear why in certain patients with CVI atrophie blanche will occur, while in
others it will not. Is there is a difference in reaction pattern on venous
hypertension in CVI patients with and without atrophie blanche? The aim of the
study was to assess the effect of stepwise induced venous hypertension on
capillary flow in atrophie blanche in the medial ankle area in patients with CVI,
and in the medial ankle area without atrophie blanche in patients with CVI. Is
there a difference in reaction pattern between these two groups of patients?
PATIENTS AND METHODS
Patients
Nine patients, 7 non-smokers (1 male, 8 females, average age 65.3 years (range 51-
78), known with clinical signs of CVI with atrophie blanche (group 1) and 5
patients (2 males, 3 females, average age 68.6 years (range 65-74) with the same
clinical signs of CVI without atrophie blanche (group II), all non-smokers, were
selected. The severeness of CVI was determined with light reflection
rheographie.^ Mean venous refilling time was equal in both groups (8.7 versus 7.9
s). Exclusion criteria were diabetes mellitus, arterial insufficiency (ankle/arm
index <0.8) and well known haemostatic disorders. Two patients were known
with mild hypertension (treated).
Methods
Capillary microscopy was performed with a Wild-Leitz microscope as described
before.^ The microscope was equipped with a lOx objective (Leitz L10; numeric
aperture 0.3). Incident illumination was performed using a Leitz Ploemopak
system and a POL-cube; light came from a 100 Watt mercury arc. Skin
transparency was enhanced by a drop of paraffin oil. The microscopic images
were projected onto the sensitive surface of a video camera (Philips), and were
recorded on videotape (Sony, Betamax) for off-line analysis.
In the centre of the atrophie blanche lesion one tortuous capillary was selected. In
this capillary, capillary blood cell velocity was determined by the flying spot
method.'-* Furthermore, the number of standstills in flow and the duration of each
standstill was determined. Measurements were performed in the venous part of
the capillary loop. The diameter was measured in the middle of the part of the
vessel in which capillary blood cell velocity was assessed. In patients without
atrophie blanche a capillary was selected in the region 5 cm above the medial
ankle.
Procedure
Patients refrained from smoking and caffeine drinking during the last two hours
before the measurements. All measurements were performed in a temperature
controlled room (24"C) in the afternoon. Patients were placed in a comfortable
supine position. The study was performed in CVI skin of the leg with and without
atrophie blanche lesions, located dorsal and proximal of the malleolus medialis. In
order to study the CVI skin disorders with the leg in a stable relaxed position, the
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leg was restrained in a brace without influencing the microcirculation. A
pneumatic tourniquet was placed around the thigh of the leg being measured.
After an acclimatisation period of 15 minutes baseline recordings were made
followed by venous hypertension pressure steps of 5 minutes each (congestion
pressure: 20, 40, 60 and 80 mmHg). During each pressure step, measurements
were performed. Measurements were performed either in the centre of the
atrophie blanche lesion or about 5 cm above the medial malleolus in patients
without atrophie blanche.
Statistics i
Data are presented as median with their inter quartile ranges. A Graphpad instat
software package was used. Results were statistically compared using Wilcoxon's
paired signed rank test, or in the case of inter group comparisons, the Mann-
Whitney U test. A p value of < 0.05 was considered statistically significant.
RESULTS
Results are summarised in figure 1 and table 1. All patients with atrophie blanche
showed the typical glomerulus-like, enlarged capillaries [figure 2]. The patients of
group II showed enlarged capillaries, although no really glomerulus-like
capillaries were seen. The baseline diameter of capillaries in patients of group 1
was 12 ± 4 um and in patients of group II 9 ± 6 um. This difference was not
statistically significant.
FIGURE 1
Mean capillary blood cell velocities (CBCV) in mm/s in patients with CVI with
atrophie blanche (group I) and without atrophie blanche (group II).
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FIGURE 2
Typical glomerulus-like capillaries.
D3-n 15: ir.nh: IU
TABLE 1
Total number of standstills per minute and standstills longer than 10 seconds in 9
patients with CVI with atrophie blanche (group 1) and 5 patients with CVI without
atrophie blanche (group II) per minute during venous hypertension. P value
represents the difference of mean number of standstills between group I and II at
the same venous pressure step. Data are presented as median values (interquartile
ranges).
Cuff pressure
OmmHg
20 mmHg
40 mmHg
60 mmHg
80 mmHg
Group I
median
0
0.2*
(0-0.8)
1.6*
(0.2-2)
1.2
(0.8-2)
1.7
(0.2-2.2)
>10s
0
0
0
0.02
0.70
Group
median
0
0.2*
(0.2-0.4)
0.4
(0.2-1.2)
0.8
(0.6-1)
0.7
(0.4-1.5)
II
>10s
0
0
0
0.08
0.10
P value
NS
NS
NS
p < 0.05
NS
* Significant compared with previous venous occlusion values
NS= not significant (atrophie blanche compared with CVI)
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Capillary blood cell velocity and capillary blood cell velocity before and during
venous hypertension were similar in both groups [figure 1]: blood cell velocity
decreased during the successive pressure steps. In almost all patients both with
and without atrophie blanche flowmotion was seen at 40 mmHg and higher
pressure steps.
Standstills were seen in both groups during all venous pressure steps [table 1]. An
increase in number of standstills was seen during subsequent pressure steps, the
increase already statistically significant at 20 mmHg. In patients of group I the
number of standstills increased significantly at the pressure step from 20 to 40
mmHg, while this was not seen in group II. Although the standstills were only
quantified in one capillary per patient, other capillaries exhibited a similar
pattern. The number of standstills tended to be higher in the patients with
atrophie blanche, although this was only statistically significant at 60 mmHg. The
duration of the standstills ranged from 2 to 48 seconds. Standstills longer than 10
seconds (10-48 s) were seen in 4 out of 9 patients of group I and 3 out of 5 patients
of group II. Standstills longer that 10 seconds were only seen at 60 and 80 mmHg.
Standstills occurred during the whole period of venous hypertension. The total
length of stop in bloodflow (number of standstills x duration of standstills)
increased with increasing pressure steps [figure 3].
FIGURE 3
Total duration of standstill (number of standstills x duration) in capillaries of
patients with CVI without atrophie blanche (CV1) and with atrophie blanche (AB).
•—group I
• - group II
mmHg cuff pressure
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DISCUSSION
Changes in capillary blood cell velocity in the medial ankle may play an important
role in the aetiology of the clinical signs of CVI. Our study showed that venous
hypertension, induced by an upper thigh cuff, results in a significant reduction in
capillary blood cell velocity and a significant increase in number of standstills in
capillaries of the skin at the ankle area of patients with CVI with and without
atrophie blanche in lying position. There in no difference in reaction pattern
between patients with and without atrophie blanche. There was no significant
difference in the diameter of capillaries, although the diameter of capillaries in
atrophie blanche showed a tendency of a larger diameter. The diameters of the
capillaries were similar to the diameters measured by Stiicker, who found a
diameter of 10 urn for mild CVI, 16um for atrophie blanche lesions and 8.5 pm for
healthy controls.^
Capillary microscopy is only possible when the leg is in a stable position. This
technique can be performed the best when the patient is in supine position.
Patients with CVI and healthy controls are, however, only during walking
different, concerning their venous haemodynamics. The key difference is the
walking venous pressure. By using a horizontal pressure model, as it was
developed for horizontal venous pressure measurements, we simulated the
condition of walking venous hypertension.
We studied the effect of stepwise increase in venous pressure, while most studies,
determining the effect of venous hypertension on the microcirculation, assess
changes at one level of venous hypertension. This is more reliable since venous
hypertension is not continuously stable. The reduction in capillary blood cell
velocity appears to be almost linearly dependent on the applied pressure of the
upper thigh cuff. At 40 mmHg a kink in this line is seen and capillary blood cell
velocity decreases less than would have been seen in a complete linear response.
This pattern is seen in both groups of patients.
There are several theories explaining a decrease in capillary blood cell velocity
during venous pressure such as the venivasomotor reflex and the myogenic
autoregulation. It is also possible that the decrease in perfusion pressure itself
causes a decrease in blood cell velocity. A loss of postural vasoconstrictor reflex
might cause the kink in decrease in capillary bloodcell velocity. Luetolf suggested
a loss of postural vasoconstrictor reflex in patients with CVI when he studied the
difference in perfusion of capillaries in the medial ankle region of healthy
volunteers and of patients with CVI.'* He found a capillary under perfusion in
patients with CVI. A reduction of capillary perfusion during venous pressure was
seen in healthy controls and not in patients with CVI. Weindorf demonstrated a
dilatation in capillary vessels during sitting and standing position."'
The efflorescencies of patients with and without atrophie blanche is dramatically
different. Since the functional alterations observed with capillary microscopy are
the same, it is suggested that the clinical signs of CVI are based on the same basic
alterations of the skin microcirculation. Local factors as disturbed fibrinolysis,
extravasation of erythrocytes and extra cellular matrix, will be responsible for the
difference in skin manifestations the course of CVI. Atrophie blanche is only a
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clinical entity correlated to be a more severe stage than CVI without atrophie
blanche.
In the present study all patients but one showed capillary standstills as a result of
venous hypertension. The higher the venous pressure, the more standstills were
seen. Standstills longer than 10 seconds were only seen in 7 of the 14 patients, at
venous pressures of 60 and 80 mmHg.
The origin, importance and complications of these standstills are unclear. This
study shows no difference in reaction pattern in patients with or without atrophie
blanche. Standstills might be a first event for developing microthrombi or
standstills might be the result of microthrombi. Standstills are probably a normal
physiological reaction on venous hypertension, since they are both seen in nailfold
capillaries of healthy controls and in the medial ankle region.
The total duration of standstill of the blood during venous pressure is relatively
high at higher venous pressure steps. Patients with CVI have a continuously
increased venous pressure during the day, and so probably a long duration of
standstill in flow will occur compared with healthy controls. It has been well
demonstrated that the fibrinolysis in patients with varicose veins and/or CVI is
decreased and that the fibrinolytic function of capillary endothelium of these
capillaries is diminished, adding a potential synergistic effect to the increased
standstills.'^" Especially in atrophie blanche lesions there are strong indications
that microthrombi are caused by local coagulation disorders and impaired
fibrinolysis, which may be partly based on diminishing flow, partly on yet
unknown mechanisms. Standstills of the blood by themselves can be, according to
Virchow, a luxating moment for thrombosis. In addition, it is known that during
venous hypertension leucocytes adherence to the endothelial cells, and release
toxic oxygen metabolites and proteolytic enzymes, resulting in damage to the
capillaries; this might contribute to the increase in the standstills.^ Standstills in
capillaries in the medial ankle region area may therefor form an increased risk in
patients with CVI. There are circumstantial evidence for the hypothesis of
microthrombi. The role of white cell trapping is less clear.
It would be interesting to study the difference in reaction pattern at the medial
ankle of patients with and without CVI. In this region, however, capillaries of
healthy controls are hard to study because only small comma shaped dots are
seen.
The effect of venous hypertension on blood cell velocity in capillaries in nailfolds
of healthy control has been studied by Fagrell and Ostergren.w In the study of
Ostergren ef a/, venous hypertension (50 mmHg) induced a decrease in blood cell
velocity in nailfolds capillaries to 14% (from 0.59 to 0.08 mm/s).™ Fagrell and his
group studied the effect of 7 minutes of venous pressure (40 mmHg) in blood cell
velocity in nailfold capillaries of 7 healthy volunteers." They found a basic blood
cell velocity of 0.39 mm/s, which decreased to 30%, (to 0.12 mm/s) during venous
pressure. The differences in basic capillary blood cell velocity may be explained by
measurements in different parts of the capillary, however, both above mentioned
studies did not state in which part of the capillary loop measurements were
performed. In our study measurements were performed in the venous part of the
capillary loop. It must be realised, however, that venous and arterial loops are
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hard to distinguish since the capillaries in this area in patients with CVI are
glomerulus like. In the above mentioned studies, as in our study, only one
capillary was studied.
The smaller decrease in capillary blood cell velocity during venous pressure in our
patients (43% at 40 mmHg and 35% at 50 mmHg) may be explained by a
combination of increased resistance of the vessel wall of capillaries and a
diminished postural vasoconstrictor reflex in patients with CVI.
It is hypothesised that increased venous pressure probably causes several events
like damage of the endothelium, decreased fibrinolysis, sludge formation,
standstills of blood flow and white cell trapping. These facts together might result
into increased platelet aggregation and finally the formation of microthrombi.
It is concluded that patients with CVI with and without atrophie blanche show a
diminishing capillary flow during venous hypertension, together with an
increasing number of standstills. Both a diminishing capillary flow and a
increasing number of standstills, together with other events like a decreased
fibrinolytic function of capillary endothelium, will form an increasing risk for the
formation of microthrombi in patients with CVI. A similar etiological factor in
patients with CVI with and without atrophie blanche is suggested. Local factors
are probably the cause for the differences in clinical appearance. Further studies
with healthy controls and CVI patients with and without atrophie blanche are
necessary.
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ABSTRACT
Objective
To study the prevalence of factor V Leiden mutation in patients with chronic
venous insufficiency and venous leg ulcers, compared with a control group and to
find out whether factor V Leiden mutation is more frequent in patients with
chronic venous insufficiency and a positive history of deep venous thrombosis.
Design
A case control study.
Setting
Three outpatient dermatological clinics.
Patients
A total of 92 patients (37 men, 55 women) with venous leg ulcers and 53 control
patients (23 men, 30 women).
Main Outcome Measures
Factor V Leiden mutation.
Results
Factor V Leiden mutation was significantly more frequent in patients with chronic
venous insufficiency and venous leg ulcers than in the control group (23% versus
7.5%, p=0.03), and the patients with factor V Leiden mutation were more likely to
have a history of venous thromboembolism (91% versus 48%, p=0.002). Also
recurrent deep venous thrombosis (38% versus 14%) and recurrent leg ulcers (9
episodes or more) occurred more frequently in the patients with factor V Leiden
mutation (43% versus 19%, p=0.01). No difference was observed in venous refill
time, or in the presence of dermatoliposclerosis and atrophie blanche.
Conclusions
Factor V Leiden mutation is more frequent in patients with venous leg ulcers than
in the control group and the general population. Patients with factor V Leiden
mutation have an increased risk of developing deep venous thrombosis and
recurrent leg ulcers.
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INTRODUCTION
Venous leg ulceration is a significant health problem for both patients and
clinicians. It forms the end stage of the complex of symptoms of chronic venous
insufficiency (CVI). Epidemiological studies have estimated the prevalence of
severe CVI to be between 6 and 8%, whereas 0.5 to 2% of the general population is
affected by venous leg u lcers .^
In 50% of patients with leg ulcers a history of deep venous thrombosis (DVT) is
seen.'' In this group of patients the diagnosis of venous thrombosis has often been
based on "clinical signs and symptoms". Only a limited percentage of patients
suspected of DVT really had the disease. Their proportion is dependent on referral
and selection.^
Activated protein C (APC) resistance, as a frequently occurring hereditary risk
factor for DVT, was first described by Dahlback ef <?/. in 19937 One year later the
genetic defect, known as factor V Leiden mutation, was identified by Bertina ef a/.®
The prevalence of the factor V Leiden mutation is estimated to be 5 to 6% in the
general population in Europe,'-™ and 3 to 5% in the Netherlands."-^
The activated form of coagulation factor V (Va) plays an important role in the
generation of thrombosis. To prevent excessive thrombus formation factor Va is
inactivated by APC. This efficient negative feedback mechanism is disturbed in
patients with factor V Leiden mutation because the mutation is located on one of
the major APC-cleavage sites, leading to so called APC resistance.
Heterozygous factor V Leiden mutation increases the risk of venous thrombosis 5-
7 fold. APC resistance accounts for 20% of the cases of DVT's, and for 50% of
familial venous thrombosis."-"'''' Leg ulcers represent one of the most serious
complications of the postthrombotic syndrome.
For screening APC resistance, functional coagulation tests, such as determination
of activated partial thromboplastin time, can be used. The gold standard is
polymerase chain reaction analysis of genetic D N A . w
The aim of this study was to investigate:
a) the prevalence of factor V Leiden mutation in a large group of patients with
CVI and venous leg ulcers;
b) whether factor V Leiden mutation is seen more frequently in patients with CVI,
with or without a history of DVT;
c) whether the prevalence of factor V Leiden mutation in our group of patients is
higher than in the general population or in the control group.
PATIENTS AND METHODS
Patients
During an 8 month period, 92 patients (37 men, 55 women, age range 38-97 years)
from the outpatient dermatological clinic of the University Hospital Maastricht,
the Hospital De Tjongerschans in Heerenveen and Canisius Wilhelmina Hospital
in Nijmegen were studied. All patients were treated for venous ulcers, classified as
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Widmer stage III (active venous ulcer or history of recurrent venous ulcer).' The
exclusion criteria was severe arterial insufficiency (ankle/arm index < 0.6).
As a control group 54 patients (age- and sex-matched) with isolated
nonmetastasized nonmelanoma skin malignancy (basal cell carcinoma and
squamous cell carcinoma) without a history of venous leg ulcers were studied.
Informed consent was obtained from all patients.
TABLE 1
Data of characteristics of 92 patients with venous leg ulcers. Data are presented in
mean values (ranges).
Sex
Men
Women
Mean age
(years)
63.5
(38-90)
71.6
(48-97)
Total of ulcers in
past
5.6
(1-20)
6.3
(1-20)
LRR
(seconds)
8.2
(4-20)
9.2
(4-20)
History
ofVTE
22
(10>lx)
31
(4>lx)
Number
of pat
38
54
VTE = deep venous thrombosis or pulmonary embolism.
LRR indicates venous refilling time (light reflex rheography)
Methods
A detailed history of venous thromboembolism (VTE) and leg ulcers was obtained
in all selected patients. The presence of clinical abnormalities, such as dermatoli-
posclerosis, atrophie blanche and haemosiderine pigmentation were noted. Light
reflex rheography was performed as described by Neumann and Boersma.'* A
venous refill time of 20 seconds or less was considered abnormal. The
characteristics of the patients are listed in table 1.
The difference in the prevalence of factor V Leiden mutation between the patients
and the control group of patients was investigated.
DNA was isolated from peripheral blood leukocytes by standard methods.' The
relevant region of exon 10 of the factor V Leiden gene was amplified by
polymerase chain reaction. After amplification and subsequent digestion, the
products were visualised on 2.5% agarose gels.s
Statistics
The results were statistically compared with those of Student T tests, Mann-
Whitney and Chi-square tests. Confidence intervals (CIs) were calculated
according to the method especially for case control data, on the basis of a binomal
distribution.'?
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RESULTS
Twenty-one of the 92 patients showed factor V Leiden mutation, 20 patients with a
heterozygous pattern and 1 patient with a homozygous factor V Leiden mutation
[table 2]. The difference of prevalence in men (32%) and women (16%) was not
significant.
TABLE 2
Age (years)
FV Leiden mutation
Patients
68.3
23%
Controls
65.9
7.5 %
In the control group of 53 patients (30 women, 23 men, average age of 65.9 years)
factor V Leiden mutation was detected in 4 patients [table 3]. Factor V Leiden
mutation was seen significantly more often in the group of patients with leg ulcers
than in the control group (p=0.03, chi square, odds ratio, 95% CI 1.17-11.19).
In patients with factor V Leiden mutation, a history of VTE was more frequent
(91% versus 48%, p=0.002, chi square). A history of recurrent DVT was seen in 8
(38%) of 21 patients with factor V Leiden mutation and in 10 (14%) of 71 patients
without factor V Leiden mutation (p=0.03, Odds ratio 3.8, 95% CI 1.24-11.32).
Factor V Leiden mutation was associated with an increased prevalence of venous
leg ulcers, ulcers during 9 episodes or more was seen in 43% in patients with
Factor V Leiden and in 19% in patients without the mutation (p=0.011, Odds ratio
4, 95% CI 1.39-12.03). There was no association between recurrent DVT and the
number of recurrences of leg ulcers or between factor V Leiden mutation and the
presence of atrophie blanche or dermatoliposclerosis.
The average age of the patients with factor V Leiden was not different from that of
the other patients. The average venous refill time was the same in both groups (8.9
s versus 8.7 s).
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TABLE 3
Prevalence rates of (recurrent) VIE, number of leg ulcers and clinical
characteristics in patients with venous leg ulcers, with (group 1) and without
(group 2) factor V Leiden mutation
Number of
patients (M/F)
History of
VTE (M/F)
History of
recurrent VTE
Average age
Number of leg
ulcers in past
Patients with >9
ulcers in past
Light Reflex
Rheography
Atrophie Blanche
Dermato- et liposcle -
rosis
Group 1
21 (12/9)
(23%)
19 (11/8) *
(91%)
8 ** (38%)
65.0 years #
range (39-97)
7.0 #
range (1-20)
Q ***
43%
8.9 s #
range (4-19)
17 (2 unknown) #
(81%)
10 (2 unknown) #
(48%)
Group 2
71 (25/46)
(77%)
34 (11/23) (48%)
10
(14%)
69.2 years
range (38-90)
5.8
range (1-20)
11
16%
8.7 s
range (4-20)
52 (8 unknown)
(73%)
42 (13 unknown)
(59%)
# Not significant in both groups
* Significant difference in patients with and without factor V Leiden mutation,
p= 0.002
** Significant difference in patients with and without factor V Leiden mutation,
p= 0.03
*** Significant difference in patients with and without factor V Leiden mutation,
p= 0.01
VTE = deep venous thrombosis or pulmonary embolism
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DISCUSSION
Chronic venous insufficiency (CVI) resulting in leg ulcers has a large impact on
quality of life.^ The present study shows a significantly increased prevalence of
factor V Leiden mutation of 23% in patients with venous leg ulcers, compared
with a prevalence of 7.5% in the control group (p=0.03, chi square). Our study
results confirm the recently reported APC resistance rate of 26% in patients with
venous leg ulcers." In the study by Munkvad ef a/, gene mutations were not
investigated. Another study by Grossman ef «/., found a much lower prevalence of
factor V Leiden mutation (7.7%). However, their patient group was rather small
(26 patients).™ These differences clearly show the importance of DNA analysis in
confirming the diagnosis of factor V Leiden mutation.
In our study patients with a history of venous thromboembolism (VTE) were
found mostly in the mutated factor V Leiden patient group. These results suggest
that patients with the combination of VTE and factor V Leiden mutation have an
increased risk of developing venous leg ulcers. However, the fact that the clinical
history with respect to DVT is not always reliable, should be taken into
consideration. In the past, duplex sonography was not available, and other
techniques, such as phlebography and impedance plethysmography, were
certainly not routinely used in all cases. To date, there are at this moment no
additional diagnostic procedures, such as photoplethysmography, which is an
accepted screening method for the haemostatic consequences of CVI, to predict
increased risk for leg ulcers, since venous refill time was the same in both patient
groups.
The association between recurrent leg ulcers of more than 9 episodes and factor V
Leiden mutation indicates that the presence of factor V Leiden mutation
represents a high risk for recurrent venous ulcers.
Recurrent venous thrombosis was three to four times more frequent in the group
of patients with factor V Leiden mutation. These data support the hypothesis that
patients with factor V Leiden mutation may require prolonged anticoagulation
therapy, as suggested by Ridker ef fl/.™ They reported a four- to fivefold increased
risk of recurrent venous thrombosis in patients with factor V Leiden mutation,*'
whereas others did not observe such an increased risk.22
As a control group patients with solitary uncomplicated skin malignancies were
studied. Although these individuals do not represent the "healthy" population, no
increased prevalence of DVT is seen in this group of patients, opposed to patients
with internal or metastasised malignancies.^ It should be taken into account that
the patients with CVI seen by us in the outpatient clinic are patients with more
severe complications; they might not be representative of all patients with venous
leg ulcers.
Beside venous thrombosis in macrocirculation, microthrombi in microcirculation
are thought to play an important role in the pathogenesis of venous leg ulcers.^ It
is not unlikely that during ulceration microthrombi are formed and that
thrombotic events in macrocirculation and in microcirculation are related. The
high percentage of factor V Leiden mutation in patients with venous leg ulcers
supports this theory.
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The role of compression therapy and anticoagulation in preventing
postthrombotic complications should be considered. The importance of
compression therapy for two years after DVT has been diagnosed, has recently
been demonstrated.^ The rate of postthrombotic syndrome was reduced by 50%
by the use of compression stockings.
Lower rates of recurrent idiopathic DVT during 6 months of oral anticoagulant
therapy instead of 6 weeks support the hypothesis that patients with DVT and
factor V Leiden mutation may require an increased period of anticoagulant
therapy.*> Long-term aspirin therapy in the group of patients with recurrent leg
ulcers might decrease the risk of recurrent ulcers.^ Additional trials of low-
molecular weight heparin and aspirin are necessary to study the reduction of these
postthrombotic complications.
We conclude that factor V Leiden mutation is more frequent in patients with
(recurrent) venous leg ulcers than in the general population. Patients with a factor
V Leiden mutation have an increased risk of developing DVT and recurrent
venous leg ulcers. Further studies with prolonged anticoagulant and compression
therapy are necessary to decrease the risk of VTE and postthrombotic
complications.
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THE INFLUENCE OF LOW MOLECULAR WEIGHT HEPARIN IN THE
TREATMENT OF ATROPHIE BLANCHE
M.B. Maessen-Visch MD, A.J.H.M. Houben, K. Hamuly^k PhD MD,
J.C.J.M. Veraart PhD MD, H.A.M. Neumann PhD MD
Chapter 7
ABSTRACT r
Low molecular weight heparins (LMWH) have become increasingly popular since
they have proven to be both safe and effective for the prophylactics and treatment
of venous thromboembolism. They are often used in the treatment of venous leg
ulcers. The effect of LMWH on the skin microcirculation of patients with CVI is
unknown.
With the use of capillary microscopy, laser doppler perfusion imager (LDPI) and
transcutaneous oxygen (TcPCh) measurements the influence of LMWH during 10
weeks was studied in patients with CVI with atrophie blanche. Measurements
were performed on atrophie blanche lesions. Both basic values and the reaction
pattern on venous hypertension steps (20, 40 and 60 mmHg) were studied.
No statistically differences were found in TcPCh measurements, LDPI
measurements, capillary blood cell velocity and number of standstill in capillaries.
Also the reaction pattern on venous hypertension did not improve after treatment.
A possible explanation may be that in venous legs without active ulcers, a stable
situation is created, in which the effects of LMWH is not measurable.
Further studies are necessary to assess whether or not LMWH will improve the
microcirculation and therefor the healing rate of leg ulcers, and whether LMWH
are useful in the prevention of leg ulcers in patients with CVI and atrophie
blanche.
100
Low moiecuiar weight Zieparin
INTRODUCTION
Chronic venous insufficiency (CVI) and the resulting leg ulcers have a
considerable impact on quality of life.' Epidemiological studies have estimated the
prevalence of severe CVI to be between 6 and 8%. Venous leg ulcers affect 0.5 to
2% of the general population.^
Venous thrombosis play often a role in the pathogenesis of CVI. Venous
thrombosis causes valvular destruction, which results in venous reflux, leading to
CVI. In the pathogenesis of leg ulceration, not only the macrocirculation seems to
be important, but also disturbances in the microcirculation. Based on capillary
microscopic findings, Bollinger hypothesised that local microthrombi are likely to
play an important role.^ These findings are confirmed by histological findings in
patients with venous insufficiency and ulcers in which occluded vessels are seen
in the papillary dermis. In atrophie blanche lesions recurrent ulceration is more
often seen than in patients with chronic venous insufficiency without atrophie
blanche.*
Many therapies have been used in the treatment of leg ulcers, with varying results.
The combination therapy of phenformin and ethylestrenol was very successful in
the treatment of leg ulcers.?-® Five patients treated by Gilliam showed relief of pain
by the third or fourth week of treatment and had progressive healing of all lesions.
Most patients remained asymptomatic on this combination treatment.? In another
study ten patients were treated for 1 to 12 years; longstanding ulcers healed
within 4 to 8 weeks, pain decreased within 7 days and new lesions decreased in
frequency and then no longer apperaed." The effect of the combination of
ethylestrenol and phenformin is probably due to an increasing release and
synthesis of plasminogen activator, which results in improved fibrinolytic
activity.^-™ However, in 1977 phenformin was removed from the general market
by FDA decision because of its side-effects. Since ethylestrenol alone is not
effective, other drugs are suggested by Jetton and Heine to be used as a substitute
for phenformin and ethylestrenol, such as low molecular weight heparin
(LMWH).
LMWH's have become increasingly popular since they have proven to be both
safe and effective for the prophylaxis and treatment of venous
thromboembolism." •'* Beside their safety and efficacy, LMWH's have practical
advantages; because of their predictable anticoagulant effect there is no need for
laboratory monitoring or intravenous infusion and they can be prescribed 1 or 2
times a day subcutaneously, also on an out patient base."'''
In addition to anticoagulant properties, LMWH's have many other properties,
which include increasing fibrinolytic activity and suppression of inflammation
and cell mediated immunity.'''-"'
Beside their use in the treatment of thromboembolism, LMWH are prescribed in
treatment of leg ulcers.'*-^ Most leg ulcers occur in patients with venous
insufficiency.25 About 30-50% of venous leg ulcers is caused by venous
thrombosis.*'
The aim of this pilot study was to investigate if 10 weeks of LMWH's might
improve the skin microcirculation in atrophie blanche lesions. Alterations in
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microcirculation were assessed with transcutaneous oxygen (TcPCh) and laser
Doppler perfusion imager (LDPI) measurements to determine the
thermoregulartory blood flow, and with capillary microscopy to quantify the
nutritive blood flow. Both the effect on capillary blood cell velocity and number of
standstills in blood flow during venous hypertension were studied.
PATIENTS AND METHODS
Patients
Ten women known with atrophie blanche were selected from the outpatient clinic
of the University Hospital of Maastricht. Chronic venous insufficiency was
determined by venous refilling time (<20 s). Exclusion criteria were arterial
insufficiency (ankle arm index below 0.8), diabetes, hypertension, obesity,
systemic diseases or the use of anticoagulants. Mean age was 55.6 years (range 32-
73). Mean number of total ulcer's in atrophie blanche lesions in the past was 3.6
(range 2-10).
Methods
Patients were treated during 10 weeks with LMWH (Clivarin, Knoll,
Ludwigshaven, Germany, 1750 IU), subcutaneously, once a day. Before the study
and after the 10 weeks treatment period capillary microscopy, LDPI and TcPO:
measurements were performed in order to evaluate the effectiveness of LMWH.
Capillary microscopy was performed with a Wild-Leitz microscope as described
before.^* The microscope was equipped with a lOx objective (Leitz L10; numeric
aperture 0.3). Incident illumination was performed using a Leitz Ploemopak
system and a POL-cube; light came from a 100 Watt mercury arc. The microscopic
images were projected onto the sensitive surface of a video camera (Philips). The
microscope images were recorded on videotape (Sony, Betamax) for off-line
analysis. Skin transparency was enhanced by a drop of paraffin oil. For analysis
the number of standstills in flow in one capillary in atrophie blanche per patient
and the duration of standstills were determined. Capillary blood cell velocity was
determined by the flying spot method.^™ Furthermore, the number of standstills
in flow and the duration of each standstill was determined. Measurements were
performed in the venous part of the capillary loop.
LDPI measurements were performed with the PIM.Lisca version 2.4 (Linkoping,
Sweden). A full description of the laser Doppler together with evaluation of the
laser-technique is presented elsewhere."•'- The images of LDPI are displayed with
colours representing a scale of mean blood velocity."
Transcutaneous oxygen tension (TcPO )^ was measured as described earlier.**^
TcPO2 were assessed with the TCM-2 (Radiometer, Copenhague, Denmark). The
TcPO: electrodes were calibrated in room air. The core temperature was set to
44"C. Constant registration of TcPO2 values occurred during the procedure.
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PROCEDURE
Patients refrained from smoking, eating and caffeine drinking two hours before
measurements. All measurement were performed in a temperature controlled
room (24°C) in the afternoon. Patients were placed in a comfortable supine
position. The leg was restrained in a brace, without influencing the skin
microcirculation. A pneumatic tourniquet was placed around the thigh of the leg
being measured.
After an acclimatisation period of 15 minutes baseline recordings were made with
the capillary microscopy in the atrophie blanche lesions, followed by venous
occlusion pressure steps of 5 minutes each (20, 40 and 60 mmHg). In the centre of
the atrophie blanche lesion one tortuous capillary was selected in which capillary
blood cell velocity, the number of standstills in flow and the duration of each
standstill was determined. Measurements were performed at each venous
pressure step measurements.
After another period of 15 minutes, LDPI measurements were performed in a
completely dark room. The distance between the measured skin and the LDPI was
20 cm. The first measurement was performed on a square skin section (36 mm x 36
mm) in an almost complete atrophie blanche lesion; subsequent measurements
were performed at the same site after 2 and 5 minutes after inflating the
tourniquet to 20, 40 and 60 mmHg for 5 minutes each. The last measurement was
performed 30 seconds after deflation. Each measurement took 60 seconds. For all
scans, the mean perfusion in millivolts (mV) and the standard deviation (SD) were
calculated by the computer. The venoarteriolar response (VAR), which was
determined for each venous pressure step, was defined as the ratio of the basic
resting flux (BRF) minus the flux during venous occlusion (VOC) and the basic
resting flux (BRF-VOC):BRF).
Finally, TcPCb measurements were performed in atrophie blanche lesions, before
as well as during the various venous occlusion steps. After stabilisation period of
about 30 minutes, the tourniquet was inflated to 20, 40 and 60 mmHg for 5
minutes each.
Statistics
A Graphpad instat software package was used. Results were statistically compa-
red using Wilcoxon's paired signed rank test. A /? value of <0.05 was considered
statistically significant.
RESULTS
Capillary blood cell velocity showed a tendency to increase as a result of LMWH,
before as well as during the different venous occlusion steps, but the difference
was again not statistically significant. Standstills in capillary flow in reaction to
venous hypertension decreased after treatment with LMWH [table 1J. This
difference was, however, not significant. Total duration of standstills (number of
stops x duration) did not decrease significantly [figure 2].
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FIGURE 1
Mean capillary blood cell velocity in mm/s in atrophie blanche, before and after
10 weeks of treatment with LMWH.
—•—befor
' • - after
mmHgcult pressure
TABLE 1
Number of standstills per minute in capillaries before and after 10 weeks of
treatment with LMWH. Measurements were performed at different venous
occlusion steps of 5 minutes each in atrophie blanche. No statistically significant
changes were observed as a result of treatment. Data are presented as median
values (interquartile ranges)
VENOUS OCCLUSION
PRESSURE
0 mmHg
20 mmHg
40 mmHg
60 mmHg
BEFORE
0
(0-0)
0
(0-0)
0.8
(0-1)
1.6
(0.6-3.9)
AFTER
0
(0-0)
0
(0-0)
0
(0-0.5)
0.4
(0-0.9)
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FIGURE 2
Total duration of standstill in blood flow (number of standstills x duration) during
5 minutes in atrophie blanche, before and after 10 weeks of treatment with
LMWH.
20 40
mmHg cufi pressure
Table 2 and 3 show data of the thermoregulatory perfusion and the venoarteriolar
response respectively in atrophie blanche lesions in reaction to venous
hypertension before and after treatment with LMWH. Median resting flow was
not influenced significantly. This also holds for the decrease in perfusion that was
observed during the venous pressure steps. VAR seemed to improve during
treatment, although this effect was not statistically significant.
Transcutaneous oxygen values did not improve significantly after treatment with
LMWH, before as well as during the venous occlusion pressure steps [table 4].
105
C/iapter 7
TABLE 2
LDPI measurements: thermoregulator skin perfusion in millivolts (mV) in atrophie
blanche lesion before and after 10 weeks of treatment with LMWH. Measurements
were performed before, during and after venous occlusion steps of 5 minutes each.
Data are presented as median values (interquartile ranges). No changes were
observed as a result of treatment.
VENOUS OCCLUSION
PRESSURE
0 mmHg
20 mmHg
40 mmHg
60 mmHg
After
BEFORE LMWH
0.33
(0.20-0.41)
0.25
(0.19-0.34)
0.16
(0.08-0.14)
0.08
(0.04-0.14)
0.26
(0.17-0.37)
AFTER LMWH
0.33
(0.20-0.51)
0.35
(0.19-0.47)
0.18
(0.11-0.28)
0.18
(0.08-0.22)
0.35
(0.20-0.50)
TABLE 3
The venoarteriolar response (VAR) before and after 10 weeks of treatment with
LMWH. The VAR is defined as the ratio of the basic resting flux (BRF) minus flux
during venous occlusion (VOC) and the basic resting flux (100*(BRF-VOC):BRF).
No significant changes were observed as a result of the treatment. Data are
presented as median (interquartile ranges)
VENOUS OCCLUSION
PRESSURE
VAR 20 mmHg
VAR 40 mmHg
VAR 60 mmHg
BEFORE LMWH
16
(10-24)
55
(40-71)
80
(60-88)
AFTER LMWH
9
(0-15)
46
(42-53)
61
(54-72)
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TABLE 4
Transcutaneous oxygen measurements (in mmHg) in atrophie blanche before and
after 10 weeks of treatment with LMWH. No statistically significant changes were
observed as a result of treatment. Data are presented as median (interquartile
ranges).
VENOUS OCCLUSION
PRESSURE
0 mmHg
20 mmHg
40 mmHg
60 mmHg
BEFORE LMWH
12
(6-25)
10
(7-26)
7
(5-21)
5
(4-25)
AFTER LMWH
11
(6.8-21.3)
12.5
(8-19.8)
13.5
(7.3-19)
13.5
(3.8-19)
DISCUSSION
In this pilot study we assessed the effect of LMWH (Clivarin) on the
microcirculation in atrophie blanche lesions in patients with CVI. LMWH
administration for 10 weeks did not improve resting transcutaneous oxygen
values or thermoregulatory perfusion levels. The changes in resting
transcutaneous oxygen values and thermoregulatory perfusion levels in reaction
to increasing venous pressure were not affected either, although the venoarteriolar
response tended to increase. Nutritional skin microcirculation seemed to improve
during treatment with LMWH since the number of standstills and the total
duration of standstill in capillary flow during venous hypertension showed a
tendency to decrease and the capillary blood cell velocity was slightly higher at
the end of the treatment period. To our knowledge, until now, no objective
measurements are performed to study the influence of heparin on the
microcirculation in patients with CVI.
No decrease in number of standstills was found as a result of LMWH treatment,
neither did the total duration of standstill in capillary flow decrease significantly.
It can be imagined that if standstills are a normal physiological phenomenon, the
total duration of standstill in capillary flow would decrease during treatment with
LMWH's. Especially on long standstills (longer than 10 seconds) this effect might
occur. In our group of patients, however, only 2 long standstills before treatment
and 1 long standstill after treatment (during 60 mmHg cuff pressure) were seen.
Probably the group of patients studied should be larger to evaluate whether this
effect of LMWH's might occur. Also a cuff pressure of 80 mmHg would more
likely to show an decrease of standstill in capillary flow after treatment. Patients
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with CV1 have a continuously increased venous pressure (between 60 and 100
mmHg) during the day and so an effect of LMWH's may occur in this group of
patients.
Standstills in capillary flow during venous hypertension have been reported
before.^? They may play an important role in the pathogenesis of CVI. It is
unclear whether microthrombi develop due to standstills in capillary flow or that
the standstills occur as a result of local microthrombi. Particularly in atrophie
blanche, the hypothesis of microthrombi in the microcirculation, as suggested by
Bollinger', is likely to play an important role in the pathogenesis.
A possible explanation that no significant improvement was found in TcPC>2 and
LDPI measurements maybe due to the fact that a treatment period of ten weeks
was not long enough to influence the skin microcirculation, or that the group
studied was too small. Another reason maybe that the patients, which we studied,
had no active ulceration but a stable situation of the microcirculation in the leg,
with only limited signs of inflammation. In patients with ulcers inflammation
plays an important role, and maybe in that period there are changes in capillary
blood flow, with an increase in standstills. In patients with ulcers, improvement in
the microcirculation might be found during treatment with LMWH. The tendency
of a decrease in total duration of standstill in capillary flow during LMWH
treatment, which was found in the present study, may contribute to an
improvement in the healing of venous leg ulcers or decrease the risk or developing
leg ulcers. Also the role of LMWH in the suppression of inflammation and cell
mediated immunity might be of more importance in all patients with active ulcers
than in a stable situation. The result of treatment with LMWH in ulcers in atrophie
blanche, in which good wound healing was found, with a very good quality of the
skin, support this hypothesis.^" We were, however, not able to assess the effect of
LMWH's in microcirculation, although there was a tendency of improvement in
microcirculation.
Several studies show improvement in wound healing with LMWH.'"-22
Unfortunately these studies are not placebo-controlled. In one study with LMWH
treatment of foot ulcers in diabetic patients an improvement in capillary
circulation was found."* In this study LDI fluxmetry was unchanged in all
patients, while the nutritive microcirculation, as quantified by capillary
microscopy increased in 7 out of 9 patients. Improvement in nutritive
microcirculation in above mentioned study was determined by the morphology of
capillaries. No capillary blood cell velocity or standstills were measured. In the
present study no capillary density was measured, because in atrophie blanche
avascular fields are seen, together with glomerulus-like capillaries, measurements
of capillary density or percentage of "normal" capillaries might not be reliable.
Recurrent leg ulcers and deep venous thrombosis are more often seen in patients
with factor V Leiden mutation than in healthy controls.* LMWH's play an
important role in the prevention of deep venous thrombosis."•'* A relation
between thrombosis in veins of the macrocirculation and capillaries in
microcirculation may exist. In case of a connection between thrombosis in macro-
and microcirculation, treatment with LMWH might decrease the risk on the
recurrence rate of leg ulcers in patients with recurrent leg ulcers and factor V
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Leiden mutation. Further studies are necessary to prove the use of LMWH in
treatment and prevention of leg ulcers.
It is concluded that 10 weeks of LMWH treatment does not influence the skin
microcirculation in atrophie blanche, although there is a tendency of
improvement. Further studies are necessary, to objectivate the effect of LMWH
treatment on the microcirculation of CV1 skin and on healing- and recurrence rate
of venous leg ulcers and on the prevention of leg ulcers.
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CLINIC
Atrophie blanche or white atrophy is described in association with several
diseases. Extensive research of literature shows, however, that it can only be
associated with a few internal diseases, such as scleroderma and systemic lupus
erythematodus (chapter 2). Even in these diseases atrophie blanche is not really
frequently reported. An incidence of less than 1 percent seems reasonable. The
name atrophie blanche or white atrophy is preferred to livedo vasculitis.
Most frequently atrophie blanche is seen in patients with chronic venous
insufficiency (CVI). Clinically no difference can be made, between these two forms
of atrophie blanche, except that atrophie blanche as symptom of CVI is always
seen on the leg, while atrophie blanche as symptom of internal disease can be seen
on any part of the body.
CVI is a complex of symptoms caused by insufficiency of the superficial, deep or
perforating venous system, or a combination of these. One of the most severe
complications of CVI is atrophie blanche. Other severe complications are leg ulcers
and dermato- et liposclerosis. Atrophie blanche needs special attention, since
recurrent ulcers is more seen in patients with CVI with atrophie blanche than in
patients with CVI without atrophie blanche (Chapter 3). In a group patients which
we studied in a phlebological outpatient clinic, atrophie blanche was seen in more
than 30 percent of the patients with venous leg ulcers. A possible explanation for
this high percentage of atrophie blanche might be that patients with slow healing
leg ulcers and therapeutic resistant patients are more likely to visit a specialised
outpatient clinic. Of all patients with venous leg ulcers, a certain percentage of
these patients will never visit a doctor at all, while another percentage will only
visit a family doctor. So this percentage might not be representative for all patients
with leg ulcers. It does, however, indicate the importance of atrophie blanche.
Studying the percentage of atrophie blanche in patients with leg ulcers visiting a
family doctor will (probably) also not be representative, since a certain group of
patients with atrophie blanche, will visit a specialised outpatient clinic right away,
and certainly if the ulcers are recurrent.
Normally venous leg ulcers are relatively painless. Leg ulcers in atrophie blanche
lesions, however, show another behaviour, they can be very painful. This might be
another reason while this group of patients will visit a phlebological clinic more
often. Another complication of ulcers in atrophie blanche lesions is, that they show
a much more slow tendency of wound healing than other venous leg ulcers. These
facts together make it important to investigate the pathogenesis of atrophie
blanche.
In studying patients with CVI with and without atrophie blanche it is difficult to
categorise patients. The classification of Widmer' is easy to use in daily practice
but is only based on clinical signs. The Hawaii^ classification is much more
complicated, but still not complete because haemodynamic disturbances are not
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classified. Therefore the Widmer classification is still used in most studies, in
combination with venous refill time.
Basically the same pathogenesis in macrocirculation is seen in all the
complications of patients with CVI. A continuous high venous pressure during
standing and walking is transmitted retrograde to the microvascular system of the
skin. Until now it is unclear which (local) factors cause the different complications
of CVI. There are four major theories for developing skin complications and the
formation of venous leg ulcers 1) the development of fibrin cuffs around
capillaries', 2) intracapillary microthrombH, 3) white cell trapping^, and 4) the
growth factor trap hypothesis*. There are indications that especially in atrophie
blanche, microthrombi play a role in pathogenesis.
MICROCIRCULATION
Increased venous pressure in macrocirculation is transmitted retrograde to the
microcirculation leading to dilatation and enlargement and formation of
glomerulus-like capillaries. The inter endothelial spaces are enlarged and an
abnormal capillary filtration rate induces an accumulation of initially water, ions
and salts, and later also other larger plasma components in the interstitium. Skin
biopsies show furthermore an apparent proliferation of capillaries and a so-called
peri-capillary halo. The total number of capillaries is reduced, although in
histological sections the tortuous loops might give the impression of a capillary
increase. The exact pathophysiologic pathway of the development of CVI,
however, is still unsolved.
In studying the microcirculation of CVI skin, several differences between atrophie
blanche and mild CVI are seen. Transcutaneous oxygen measurements are
decreased extremely in atrophie blanche, sometimes down to zero. This might be
caused by the fact that in atrophie blanche lesions avascular fields are seen.
Bollinger explained this by the formation of microthrombi, which will result in
minor skin infarctions. This theory is supported by studies in which endothelial
proliferation and thickened and swollen capillaries and arterioles in histology are
seen. Some vessels are occluded with fibrinoid material or erythrocytes. In
patients with CVI without atrophie blanche, transcutaneous oxygen
measurements are also decreased, but they are not reaching zero. In our study a
clear difference in basic transcutaneous oxygen values was seen between atrophie
blanche and mild CVI patients. No statistically difference was seen in basic oxygen
values between healthy controls and mild CVI patients (chapter 4). A possible
explanation for this might be the small group of patients and a large interpatient
variation.
A different reaction pattern in transcutaneous oxygen values during artificially
induced venous hypertension is seen. In atrophie blanche transcutaneous oxygen
measurements show a decrease at 40 mmHg venous hypertension, while in mild
CVI a significant decrease is seen at 60 mmHg artificially induced venous
hypertension. Healthy controls show a significant decrease in transcutaneous
oxygen measurements at 80 mmHg artificially induced venous hypertension
(chapter 4). In the literature an increase of transcutaneous oxygen values during
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venous hypertension is described in both the skin of healthy controls and CVI
patients. In these studies venous hypertension was induced by a sitting position
(dependent leg). A possible explanation might be that a sitting position causes an
increase in arterial inflow, while a upper thigh cuff might cause a decrease of
arterial inflow. The decrease of arterial inflow as result of the upper thigh cuff is,
however, probably very small. Sitting position also causes a lesser increase in
venous hypertension than a upper thigh cuff of 80 mmHg does. Venous
hypertension caused by an upper thigh cuff might be a more realistic reflection of
changes in microcirculation in severe CVI than venous hypertension in sitting
position does.
In our study (chapter 4) healthy controls show a tendency of increase in
transcutaneous oxygen values at 20 and 40 mmHg, but show a significant decrease
at 80 mmHg artificially induced venous hypertension. The importance of the
differences in decrease at several levels of artificially induced venous hypertension
is unclear. An explanation for these different reaction patterns might be that the
microcirculation in atrophie blanche is more disturbed than in mild CVI. Less
extra venous pressure is necessary to induce a decrease in microcirculatory
functions since vascular reserve capacity is all used. It would be interesting to
study the reaction of venous hypertension in patients with CVI and dermato- et
liposclerosis and to compare that with our study results. Since dermato- et
liposclerosis is also a severe complication of CVI, a similar reaction pattern as in
patients with atrophie blanche is expected.
We were able to demonstrate differences in basic resting flux, measured with laser
Doppler perfusing imager in patients with atrophie blanche. Increased basic
resting flux in patients with CVI in general or dermato- et liposclerotic skin was
described before. However, no information was known about atrophie blanche. In
atrophie blanche lesions, basic flux was increased compared with healthy controls
and compared with normal skin in the knee of patients with CVI (chapter 4).
An increased basic resting flux in areas with atrophie blanche lesions can be
explained by the morphology of atrophie blanche. Laser Doppler perfusing imager
measures 1 to 1.5 mm in depth, where both a part of capillaries is seen and
arterioles and small veins. In atrophie blanche lesions the number of capillaries is
decreased so the blood volume has to pass through a decreased capacity of
capillaries. It is possible that as a result the basic resting flux is increased.
Summarised the increased flux could represent an increase in flow in arterioles
and small veins, while the number of capillaries is decreased.
A decrease in flux was seen during venous hypertension in atrophie blanche and
healthy controls. The venoarteriolar response was similar in both groups. Also a
recent study with a double-wavelength laser Doppler probe did not show an
impaired venoarteriolar response in the legs of patients with CVI compared with
healthy controls." In our study no rebound reaction was seen. This might be
explained by a lack of reserve capacity of the microcirculation. However, also
healthy controls showed no rebound reaction. It is also possible that a rebound
reaction is mainly seen after arterial occlusion.
The contradiction of increased flux and decreased transcutaneous oxygen values
in atrophie blanche lesions is hard to explain. Some authors suggest that
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arteriovenous anastomosis cause this discrepancy. A possible explanation might
also be that transcutaneous oxygen values predominantly reflects the effects
caused by the capillaries (comprising a considerable part of the nutritive vessels),
which are partly occluded by microthrombi and might be influenced by fibrin
cuffs, trapping of leucocytes and oedema whereas the laser Doppler perfusing
imager mainly reflects the flux of blood in the deeper skin layers (which mainly
serve the thermo-regulation). Chronic venous hypertension may cause a continue
increased flux in the deep vessels, and because of dilatation, a decreased flux in
the superficial vessels, which increase the risk for developing microthrombi.
Decreased transcutaneous oxygen values and decreased number of capillaries in
atrophie blanche support this hypothesis.
More details about the microcirculation can be observed with capillary
microscopy. With capillary microscopy only the most superficial capillaries can be
seen. Because atrophy blanche lesions are atrophie, this skin is easier to study with
capillary microscopy than skin of healthy controls.
We were able to demonstrate a decrease in capillary blood cell velocity during
different steps of artificially induced venous hypertension in capillaries of CVI
skin (chapter 5). There was also an increase in the number of standstills and the
total duration of standstill (times x duration) during increasing venous
hypertension. No difference was seen in reaction pattern during venous
hypertension in patients with CVI with atrophie blanche and without atrophie
blanche, although there was a tendency of increased number of standstills in
atrophie blanche lesions compared with CVI skin.
The origin, importance and complications of these standstills are unclear.
Standstills are probably a normal physiological reaction on venous hypertension,
since they are both seen in nailfold capillaries of healthy controls and in the medial
ankle region.
Standstills might be a first event for developing microthrombi or standstills might
be the result of microthrombi. Both reduction in capillary flow and the number of
standstills are likely to play an important role in formation of microthrombi. It is
known that endothelium of capillaries in CVI skin are damaged and that
leucocytes adhere to the endothelial cells. The nature of active leucocytes
adherence is not fully understood, however, adherence proteins (like intercellular
adhesion molecule (ICAM-1) and endothelial leucocyte adhesion molecule
(ELAM-1)) do play an important role. Veraart e< n/. found a moderate to strong
expression of ELAM-1 under leg ulcers, and no up-regulation of ICAM-1 along the
border area of a ulcer.® Other studies in the expression of ICAM-1 and ELAM-1 in
liposclerotic skin and healthy controls skin showed no significant difference.
Adherence of the leucocytes may cause partial obstruction of the capillary lumen
and reduce bloodflow. In addition patients with CVI show a decreased
fibrinolysis. These facts together may cause microthrombi in CVI skin, while in
other places, decrease in capillary flow and standstills cause no microthrombi.
The efflorescencies of patients with CVI with or without atrophie blanche and/or
with or without dermato- et liposclerosis is extremely different. It is suggested that
the clinical signs of CVI are based on the same basic alterations of the skin
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microcirculation. Local factors as disturbed fibrinolysis, extravasation of
erythrocytes and extra cellular matrix, will be responsible for the difference in skin
manifestations in the course of CV1. Arrophie blanche is only a clinical entity
correlated to be a more severe stage than CV1 without atrophie blanche. It is clear
that increased venous walking pressure results into decreased capillary density
and dilated, tortuous capillaries with halo formation. A decreased flow in
capillaries leads to sludge formation and stasis, resulting together with leucocyte
adhesion and local coagulation disorders into intravascular coagulation, decreased
TcPO2 and microthrombi.
Further studies are necessary to elucidate the pathogenesis. It would be interesting
to study the differences in bloodcell velocity and standstills in capillaries during
venous hypertension in the medial ankle region in healthy controls and patients
with CVI. Patients with CV1 should be categorised in mild CVI, CVI with
dermato- et liposclerosis and CVI with atrophie blanche. Studies with capillary
microscopy in dermato- et liposclerosis without the use of sodium fluorescence is,
however, almost impossible. Also in healthy controls the skin in the medial ankle
region only show comma shaped capillaries, in which it seems impossible to
measure capillary blood cell velocity. Besides capillary bloodcell velocity and
standstills the morphological abnormalities of the capillaries can be studied. This,
however, will also be difficult because the different patterns described for
capillaries can be applied on nailfold capillaries, but not on capillaries of other
parts of the skin. It is also not very likely that the tortuous capillaries will change
to normal capillaries. Recently, the effect of compression-therapy on
microcirculation was studied with capillarymicroscopy.'* Capillary density
increased during therapy. Capillary density, however, also seems a more
appropiate method for mild CVI than CVI with atrophie blanche.
FACTOR V LEIDEN
Both thrombi in micro,- and macrocirculation might play a role in the
pathogenesis of CVI. In 30 to 50 percent of patients with CVI and leg ulcers, a
history of deep venous thrombosis is seen. Deep venous thrombosis can be caused
by several factors. Recently a high prevalence of factor V Leiden mutation in
patients with deep venous thrombosis was studied. Heterozygous factor V Leiden
mutation increases the risk of venous thrombosis 5-7 fold. Factor V Leiden
mutation accounts for 20% of DVT's, and for 50% of familial venous thrombosis.
We studied the prevalence of factor V Leiden mutation in a group of 92 patients
with CVI and venous leg ulcers and a control group of 53 patients to investigate
whether factor V Leiden mutation is seen more in CVI patients and especially in
patients with CVI with atrophie blanche (chapter 6). Factor V Leiden mutation
was seen significantly more in patients with CVI and venous leg ulcers than in the
control group (23% versus 7.5%).
In the patient group with factor V Leiden mutation a history of deep venous
thrombosis and pulmonary embolism was more present. Also recurrent deep
venous thrombosis and recurrent leg ulcers of 9 times or more, was seen
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significantly more in this group of patients. No difference was seen in venous refill
time, or presence of atrophie blanche and/or dermato- et liposclerosis.
Patients with factor V Leiden mutation have an increased risk in developing deep
venous thrombosis and recurrent leg ulcers. Since no difference was seen in
patient groups with atrophie blanche or dermato- et liposclerosis, a relation
between thrombi in macrocirculation and thrombi in microcirculation could not
be estimated.
Concerning the results of the studies in atrophie blanche lesions and patients with
CVI, as mentioned above, a different reaction pattern in several complications of
CVI is sometimes suggested. A closer analysis of the results, however, makes it
more likely that complications of CVI are the result of the same mechanism with
different stadia. These different stadia, which can change in time, may sometimes
suggest different reaction patterns. Further studies are necessary to investigate the
effect of compression therapy and anticoagulants in preventing CVI and leg ulcers
in patients with deep venous thrombosis.
PILOT STUDY LOW MOLECULAR WEIGHT HEPARIN
In daily practice it would be interesting and of great social economic value how
complications of CVI can be prevented. It is well known that compression therapy
is a cornerstone in the treatment of CVI. But also in patients with adequate
compression therapy, leg ul'ceration is seen.
A combination of phenformin and ethylestrenol, which enhances endogenous
blood fibrinolytic activity by increasing plasminogen activating enzymes,
appeared to be effective in treating atrophie blanche ulcers. In 1977 phenformin
was removed from the general market by FDA decision because of its side-effects.
Since ethylestrenol alone is not effective, other drugs are suggested to use as a
substitute. Case reports of effective treatment in venous leg ulcers with low
molecular weight heparins suggest an alternative. We studied the influence of low
molecular weight heparin (LMWH) in the microcirculation of the skin of patients
with atrophie blanche (chapter 7). The influence of 10 weeks with Clivarin was
determined with transcutaneous oxygen measurements, laser doppler perfusion
imager and capillary microscopy. No improvement in basic transcutaneous
oxygen values and flux or in venoarteriolar response could be found. Basic
capillary blood cell velocity and the decrease of capillary bloodcell velocity during
venous hypertension, did not improve during treatment with Clivarin. A tendency
of decrease in number of standstills in capillary flow during venous hypertension
was seen after 10 weeks of treatment. This difference was however not significant.
It is suggestive however, that treatment with LMWH's might be successful in the
additional treatment of leg ulcers, or in prevention of leg ulcers. Maybe the used
parameters in measuring improvement of the microcirculation are not sensitive
enough, to measure improvements in the microcirculation. Also the period of 10
weeks might be too short to measure improvements in the microcirculation. It can
be concluded that further studies are necessary to measure additional effects of
drugs to compression therapy to improve complications of CVI. It would then be
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interesting not only to study the effect of LMWH's, but also of aspirin and the
combination of both. It is possible that the combination of LMWH's and aspirin
have a synergetic effect.
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Atrophie blanche is een vaak voorkomende complicatie van patienten met
chronische veneuze insufficientie (CVI). In het dagelijks leven kan atrophie
blanche pijnlijke, slecht genezende "open benen" veroorzaken, welke van grote
invloed zijn op het dagelijks functioneren van de patient.
CVI is een complex van symptcmen welke veroorzaakt wordt door een continue
verhoogde ambulatoire veneuze druk, waarbij een te geringe drukdaling in het
veneuze stelsel tijdens het lopen centraal staat. Dit wordt veroorzaakt door
insufficientie (slecht functionerende kleppen) van het oppervlakkige, perforerende
en/of diepe veneuze systeem (door de zogenaamde "oppervlakkige en/of diepe
spataders"). Bij iemand met intacte kleppen daalt de druk tijdens het lopen en
bewegen van de kuit- en voetspieren; bij defecte kleppen gebeurt dit niet en
ontstaan er bij spiercontracties drukgolven de verkeerde kant op, richting de
kleine bloedvaatjes (capillairen) in de huid. De meest voorkomende oorzaak voor
deze klepinsufficie'ntie zijn primaire varices (spataders) of een klepbeschadiging
van de diep gelegen venen na een doorgemaakt trombose been.
Naast uiting van CVI wordt atrophie blanche ook gezien in patienten met interne
afwijkingen. Klinisch kan tussen deze twee vormen van atrophie blanche geen
onderscheid gemaakt worden, behoudens dat atrophie blanche als uiting van CVI
altijd op het onderbeen gezion wordt, terwijl atrophie blanche bij interne
afwijkingen overal op het lichaam kan voor komen.
In hoofdstuk 1 wordt een overzicht gegeven over CVI en diep veneuze trombose.
In het bijzonder wordt de pathofysiologie, de microcirculatie en de behandeling
van CVI besproken en de relatie van diep veneuze trombose, stollings afwijkingen
en CVI.
Het doel van diverse onderzoeken wordt beschreven. Allereerst wilden we een
juist overzicht krijgen van de prevalentie van atrophie blanche in veneuze ulcera
("open benen"), en of de ulcera in atrophie blanche een grotere neiging hebben tot
recidiveren. Daarnaast wilden we een compleet overzicht krijgen van wat er tot op
dit moment bekend is van atrophie blanche.
Een ander doel was het verkrijgen van inzicht in het effect van artificieel
ge'induceerde veneuze hypertensie op de microcirculatie in atrophie blanche met
behulp van laser Doppler imaging, transcutane zuurstofmeting en de capillair
microscoop. We waren geinteresseerd of er een verschillend reactie patroon bij
veneuze druk optreedt bij patienten met atrophie blanche, patienten met CVI
zonder atrophie blanche en gezonde controles.
Daarnaast waren we geinteresseerd of bij patient en met veneuze ulcera en
atrophie blanche factor V Leiden vaker voor komt dan bij patienten met veneuze
ulcera zonder atrophie blanche en of er een verschil in prevalentie is ten opzichte
van gezonde controles.
We vroegen ons af of het voorschrijven van laag moleculair heparine zinvol is in
de behandeling of preventie van veneuze ulcera in atrophie blanche. Hiervoor
werd de invloed van laag moleculair heparine op de microcirculatie van atrophie
blanche bestudeerd.
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In hoofdstuk 2 wordt een algemeen overzicht gegeven over atrophie blanche.
Atrophie blanche wordt beschreven in diverse ziektebeelden, maar wordt eigenlijk
alleen regelmatig gezien in scleroderma en systemische lupus erythematodes. Het
meest frequent wordt atrophie blanche echter gezien als onderdeel van CVI. Het is
niet altijd eenvoudig om de juiste informatie over atrophie blanche te vinden
omdat diverse synoniemen gebruikt worden (meer dan 7). De naam atrophie
blanche verdient de voorkeur boven het meest gebruikte synoniem livedo
vasculitis.
Bijzondere aandacht wordt gegeven aan de pathogenese van atrophie blanche. Tot
nu toe is het onduidelijk welke factoren het meest belangrijk zijn in de
pathogenese van CVI en in het bijzonder van atrophie blanche. De belangrijkste
theorie voor de pathogenese van atrophie blanche lijkt de theorie van de
microthrombi. Volgens deze theorie vormen zich stolsels in de meest kleine
vaatjes van de huid (de capillairen), zodat als het ware kleine infarcten van de
huid optreden. Omdat in atrophie blanche grote delen zonder bloedvaatjes
worden gezien, en omdat onder de microscoop verstoppingen van diverse
capillairen wordt gezien lijkt deze theorie van toepassing op atrophie blanche.
Tevens wordt een overzicht gegeven van diverse behandelingen van atrophie
blanche. Meeste behandelingen die in de literatuur beschreven worden, zijn echter
geen goed beschreven studies, maar individuele case reports, waarin hoogstens 2
of 3 patienten beschreven worden.
In hoofdstuk 3 wordt de prevalentie van atrophie blanche in patienten met
veneuze ulcera bestudeerd. In een grote groep patienten met veneuze ulcera werd
atrophie blanche gezien in 31% van de manlijke patienten en in 44% van de
vrouwelijke patienten. Deze getallen zijn hoger dan in de literatuur wordt
beschreven. Dit kan veroorzaakt worden doordat voornamelijk patienten met een
therapie resistent ulcus een polikliniek bezoeken die gespecialiseerd is in de
flebologie. Bij patienten met atrophie blanche werden significant meer
recidiverende ulcera gezien (71%) dan bij patienten met CVI zonder atrophie
blanche. Dit onderschrijft het belang van het goed herkennen van atrophie blanche
en het belang van een goede en adequate behandeling.
In hoofdstuk 4 worden de resultaten gepresenteerd van een studie waarin de
verandering in de microcirculatie van de huid tijdens artificieel geinduceerde
veneuze hypertensie geobjectiveerd wordt met behulp van transcutane
zuurstofwaarden en laser doppler perfusion imager metingen in patienten met
CVI met en zonder atrophie blanche. Het is algemeen bekend dat in atrophie
blanche de transcutane zuurstofwaarden extreem laag zijn, bijna nul. Een
verschillend reactiepatroon op veneuze hypertensie werd gezien in de drie
bestudeerde groepen. In atrophie blanche werd een daling in transcutane zuurstof
waarden gezien bij 40 mmHg, in CVI huid zonder atrophie blanche bij 60 mmHg
en in gezonde controles bij 80 mmHg artificieel geinduceerde veneuze
hypertensie.
Flux in de huid werd gemeten met de laser Doppler perfusion imager. Flux in
patienten met atrophie blanche was significant hoger dan in CVI huid zonder
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atrophie blanche en gezonde controles. Een daling in de flux trad op bij artificieel
geinduceerde veneuze hypertensie. Deze daling was vergelijkbaar in patienten
met atrophie blanche en gezonde controles, dat wil zeggen, de venoarteriolaire
reactie was gelijk in alle bestudeerde groepen. Geen rebound fenomeen werd
gezien, wat een tekort aan reserve capaciteit van de microcirculatie veronderstelt.
In hoofdstuk 5 worden de resultaten besproken van de studie, waarin het effect
van veneuze hypertensie op de microcirculatie van de huid gemeten wordt met
behulp van een capillair microscoop. De capillair microscoop is in het bijzonder
geschikt voor metingen in atrophie blanche gebied, omdat de huid daar erg dun
is, en zo de capillairen makkelijk zichtbaar zijn. Het is bekend dat de capillairen in
dit gebied vergroot zijn en een glomerulus-achtig aspect vertonen. Twee groepen
patienten werden bestudeerd, patienten met CV1 zonder en met atrophie blanche.
Tijdens diverse artificieel geinduceerde veneuze drukstappen daalde de capillaire
bloedsnelheid en nam het aantal flow stops en de totale duur van flow stop (aantal
x duur stops) in de capillairen toe. Bij 20 mmHg vertoonden beide groepen een
significante toename in stops. Bij hogere veneuze drukken nam het aantal flow-
stops toe, maar alleen bij patienten met atrophie blanche werd nog een significante
stijging in het aantal flow-stops gezien bij stijging van 20 naar 40 mmHg. In het
algemeen kan gesteld worden dat flow-stops in capillairen ten gevolge van
drtifiVieef geiiiduceerde veneuze hypertensie een nonnaaf fysiologisch verschijnsel
zijn, daar ze zowel voorkomen bij patienten met atrophie blanche als bij gezonde
controles. Bij atrophie blanche speelt zowel een daling in capillaire bloedsnelheid,
als een toename in capillaire flow-stops en totale duur van flow stops mogelijk een
rol in de vorming van microthrombi. Bij chronische verhoogde veneuze druk is er
namelijk ook nog sprake van schade aan het endotheel van de capillairen, leidend
tot een verminderde fibrinolytische functie. Deze processen, samen met het
verstrikt raken van leucocyten in de capillairen, stimuleren waarschijnlijk de
vorming van microthrombi.
Hoofdstuk 6 behandelt de resultaten van een studie waarin de prevalentie van
factor V Leiden mutatie in patienten met veneuze ulcera bestudeerd wordt. Sinds
een aantal jaren is het bekend dat bij een grote groep patienten met een trombose
been, factor V Leiden mutatie gezien wordt. Factor V Leiden mutatie is een
afwijking op een gen waardoor het bloed als het ware sneller stolt. Het is bekend
dat bij bijna de helft van de patienten met veneuze ulcera vermoed wordt dat ze in
het verleden een trombose been hebben doorgemaakt. Bij 92 patienten met
veneuze ulcera, werd factor V Leiden mutatie gezien in 23%. In een gezonde
controle groep werd slechts in 7.5% factor V Leiden mutatie gezien. Er werd geen
relatie gezien tussen factor V Leiden en atrophie blanche. Wei was er een
duidelijke, significante relatie tussen veelvuldig recidiverende ulcera (9 keer of
meer) en factor V Leiden mutatie. Er wordt door ons verondersteld dat factor V
Leiden mutatie een verhoogd risico vormt voor het ontwikkelen van ernstige en
recidiverende veneuze ulcera. Meer studies zijn nodig om het effect van de
gecombineerde behandeling van compressie therapie en anticoagulantia op de
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preventie van CVI en veneuze ulcera bij pati6nten met een doorgemaakt trombose
been te bestuderen.
In hoofdstuk 7 worden de resultaten gegeven van de studie waarin het effect van
laag moleculaire heparine op de microcirculatie van de huid in patifinten met
atrophie blanche bestudeerd wordt. Tien patienten met atrophie blanche werden
gedurende 10 weken behandeld met het laag moleculaire heparine, Clivarine. Aan
het begin en aan het einde van de studie werden metingen van de microcirculatie
van de huid verricht met behulp van transcutane zuurstofwaarden, laser Doppler
metingen en de capillair microscoop. Niet alleen de uitgangswaarden werden
vergeleken, maar ook of het effect op artificieel gei'nduceerde veneuze hypertensie
gedurende deze 10 weken verbeterde. Er werd na tien weken behandelen geen
verbetering gemeten in de uitgangswaarden. Wel was er een duidelijke tendens in
afname van het aantal capillaire flow-stops tijdens veneuze hypertensie. Deze
afname was echter niet statistisch significant.
Hoofdstuk 8 vormt een algemene discussie, waarin de gegevens van de studies
van de voorafgaande hoofdstukken besproken worden. Atrophie blanche vormt
een ernstige complicatie van CVI, met een prevalentie van 30% . In patiSnten met
CVI en atrophie blanche worden recidiverende ulcera meer gezien dan in
patienten met CVI zonder atrophie blanche.
In de microcirculatie van de atrophie blanche huid worden diverse afwijkingen
gezien. Transcutane zuurstofwaarden zijn in dit gebied extreem laag, en dalen
tijdens "veneuze hypertensie stappen" eerder dan in CVI huid zonder atrophie
blanche. Dit veronderstelt een tekort aan reserve capaciteit in de microcirculatie
van atrophie blanche. De flux in atrophie blanche is verhoogd, vergeleken met
CVI huid zonder atrophie blanche en gezonde controles. De venoarteriolaire
reactie van beiden groepen is gelijk. Veneuze hypertensie veroorzaakt een dating
in capillaire bloed snelheid en een toename in het aantal capillaire flow stops en
totale duur van flow-stop in atrophie blanche. Deze resultaten ondersteunen de
theorie van de microthrombi.
Geen relatie werd gezien tussen atrophie blanche en factor V Leiden mutatie.
Recidiverende veneuze ulcera worden echter wel significant meer gezien in
patienten met factor V Leiden mutatie, wat een ernstiger complicatie in het post
thrombotisch syndroom veronderstelt. Factor V Leiden mutatie wordt significant
meer gezien in patienten met veneuze ulcera vergeleken met gezonde controles.
Behandeling met laag moleculair heparine's gedurende 10 weken resulteert niet in
objectiveerbare verbetering in de microcirculatie van de atrophie blanche huid,
alhoewel wel een duidelijke afname van het aantal capillaire stops tijdens veneuze
hypertensie wordt gezien. Meer studies zijn nodig om het effect van behandeling
in de preventie van atrophie blanche te bestuderen. Het zou interessant zijn of een
gecombineerde behandeling van laag moleculaire heparine en aspirine wel tot
objectiveerbare verbeteringen zou leiden, daar deze twee mogelijk een
synergistisch effect hebben.
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Chapter 9
Veel dank ben ik verschuldigd aan de patienten die iedere keer bereid waren te
participeren in diverse onderzoeken.
De verpleegkundigen, het baliepersoneel en secretaresses van de vakgroep
Dermatologie wil ik van harte bedanken voor hun inzet en bereidwilligheid mij de
afgelopen jaren te ondersteunen en te helpen zoeken naar oplossingen om
patientenzorg te combineren met wetenschappelijk onderzoek.
Alle (ex)-stafleden en (ex) -arts-assistenten wil ik danken voor hun medewerking
in de afgelopen jaren. Ja, Ivo, op atrophie blanche promoveren is echt leuk.
De medewerksters van het lab microcirculatie interne geneeskunde en in het
bijzonder Monique, wil ik bedanken voor hun medewerking.
Een speciaal woord van dank voor Nico Crombag, Babs van Hussen-Brok en
Frank Bruins die (naast Dick Groeneweg) aan de wieg van mijn carriere als
dermatoloog hebben gestaan en van wie ik in allerlei opzichten veel geleerd heb.
Mijn paranimfen. Lieve Marc en Paul, jullie wil ik bedanken voor de bijzondere
vriendschap, steun, vele discussies, etentjes en gezelligheid in de afgelopen jaren.
Zonder jullie waren de jaren Nijmegen-Maastricht voor mij een zware opgaaf
geweest. Ik heb nooit tevergeefs een beroep op jullie gedaan, zeker niet om
diensten over te nemen (van "ruilen" was al snel geen sprake meer). Marc en
Jesje, jullie gastvrijheid is zeer bijzonder. Ontelbare keren kwam ik "even" langs
en at dan geli/k mee. /uilie weten als geen ander hoe zeer ik dat waardeer.
Mijn familie en vrienden wil ik bedanken voor hun vriendschap en hun bijdrage
aan dit proefschrift, op welke manier dan ook.
Mijn moeder wil ik bedanken voor de steun en opvang de afgelopen jaren. Lieve
mama, te pas en te onpas kon ik op je rekenen. Altijd stond je voor me klaar, ook
recent weer als oppas voor onze dochter Niki om dit proefschrift af te ronden.
Lieve Michel, jou wil ik bedanken voor alle steun en je enthousiasme de afgelopen
jaren om de studie af te ronden en te promoveren en om daarnaast alles te
relativeren en te genieten van de mooie dingen in het leven. Ik hoop dat voor dit
laatste nu nog meer tijd is met jou en Niki.
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LIST OF ABBREVIATIONS
AB atrophie blanche : ;
BRF basic resting flux
CVI chronic venous insufficiency
DVT deep venous thrombosis
ELAM endothelial leucocyte adhesion molecule
ICAM intercellular adhesion molecule
LDF laser Doppler fluxmetry
LDPI laser Doppler perfusion imager
PAI plasminogen activator inhibitor
TcPO2 transcutaneous oxygen pressure
t-PA tissue plasminogen activator
SLE systemic lupus erythematodus
VAR venoarteriolar response
VOC venous occlusion
130


